<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.2 20060430//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Genomics</journal-id><journal-title>BMC Genomics</journal-title><issn pub-type="epub">1471-2164</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2164-8-16</article-id><article-id pub-id-type="pmid">17222329</article-id><article-id pub-id-type="doi">10.1186/1471-2164-8-16</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Comprehensive genetic and epigenetic analysis of sporadic meningioma for macro-mutations on 22q and micro-mutations within the <italic>NF2 </italic>locus</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Hansson</surname><given-names>Caisa M</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Caisa.Hansson@gmail.com</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Buckley</surname><given-names>Patrick G</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Patrick.Buckley@gmail.com</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Grigelioniene</surname><given-names>Giedre</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Giedre.Grigelioniene@kbh.ki.se</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Piotrowski</surname><given-names>Arkadiusz</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>apiotrowski@genetics.uab.edu</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Hellstr&#x000f6;m</surname><given-names>Anders R</given-names></name><email>hellstroem@gmail.com</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Mantripragada</surname><given-names>Kiran</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>kiran.mantripragada@gmail.com</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Jarbo</surname><given-names>Caroline</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Caroline.Jarbo@amic.se</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Mathiesen</surname><given-names>Tiit</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>mathiesen@karolinska.se</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Dumanski</surname><given-names>Jan P</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I3">3</xref><email>jdumanski@genetics.uab.edu</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, 751 85 Uppsala, Sweden</aff><aff id="I2"><label>2</label>Department of Neurosurgery, Karolinska University Hospital, Solna, SE-171 76 Stockholm, Sweden</aff><aff id="I3"><label>3</label>University of Alabama at Birmingham, 1530 3rd. Ave. S., Kaul 420, Birmingham, AL 35294-0024, USA</aff><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>12</day><month>1</month><year>2007</year></pub-date><volume>8</volume><fpage>16</fpage><lpage>16</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2164/8/16"/><history><date date-type="received"><day>12</day><month>8</month><year>2006</year></date><date date-type="accepted"><day>12</day><month>1</month><year>2007</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2007 Hansson et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>Hansson et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Hansson M Caisa Caisa.Hansson@gmail.com </dc:author><dc:title> Comprehensive genetic and epigenetic analysis of sporadic meningioma for macro-mutations on 22q and micro-mutations within the NF2 locus </dc:title><dc:date>2007</dc:date><dcterms:bibliographicCitation>BMC Genomics 8(1): 16-. (2007)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2164(2007)8:1&#x0003c;16&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2164</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Meningiomas are the most common intracranial neoplasias, representing a clinically and histopathologically heterogeneous group of tumors. The neurofibromatosis type 2 (<italic>NF2</italic>) tumor suppressor is the only gene known to be frequently involved in early development of meningiomas. The objective of this study was to identify genetic and/or epigenetic factors contributing to the development of these tumors. A large set of sporadic meningiomas were analyzed for presence of 22q macro-mutations using array-CGH in order to identify tumors carrying gene dosage aberrations not encompassing <italic>NF2</italic>. The <italic>NF2 </italic>locus was also comprehensively studied for point mutations within coding and conserved non-coding sequences. Furthermore, CpG methylation within the <italic>NF2 </italic>promoter region was thoroughly analyzed.</p></sec><sec><title>Results</title><p>Monosomy 22 was the predominant finding, detected in 47% of meningiomas. Thirteen percent of the tumors contained interstitial/terminal deletions and gains, present singly or in combinations. We defined at least two minimal overlapping regions outside the <italic>NF2 </italic>locus that are small enough (~550 kb and ~250 kb) to allow analysis of a limited number of candidate genes. Bialleinactivationo the <italic>NF2 </italic>gne was detected in 36% of meningiomas. Among the monosomy 22 cases, no additional <italic>NF2 </italic>mutations could be identified in 35% (17 out of 49) of tumors. Furthermore, the majority of tumors (9 out of 12) with interstitial/terminal deletions did not have any detectable <italic>NF2 </italic>mutations. Methylation within the <italic>NF2 </italic>promoter region was only identified at a single CpG site in one tumor sample.</p></sec><sec><title>Conclusion</title><p>We confirmed previous findings of pronounced differences in mutation frequency between different histopathological subtypes. There is a higher frequency of biallelic <italic>NF2 </italic>inactivation in fibroblastic (52%) compared to meningothelial (18%) tumors. The presence of macro-mutations on 22q also shows marked differences between fibroblastic (86%) and meningothelial (39%) subtypes. Thus, inactivation of <italic>NF2</italic>, often combined with the presence of macro-mutation on 22q, is likely not as important for the development of the meningothelial subtype, as opposed to the fibroblastic form. Analysis of 40 CpG sites distributed within 750 bp of the promoter region suggests that <italic>NF2 </italic>promoter methylation does not play a major role in meningioma development.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Meningiomas are the most frequently occurring intracranial tumors. Clinically treated meningiomas comprise approximately 13&#x02013;26% of all primary brain tumors [<xref ref-type="bibr" rid="B1">1</xref>]. Epidemiological studies indicate that ~90% of all meningiomas are asymptomatic [<xref ref-type="bibr" rid="B2">2</xref>]. The majority are benign, slowly growing, solitary and sporadic tumors, but atypical or malignant meningioma constitutes approximately 10% of all cases. Meningiomas are thought to be derived from the arachnoid cap cells of the leptomeninges, which is the covering of the brain and the spinal cord [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. They usually occur in the cranial meninges, but approximately 10% of tumors develop in the meninges covering the spine. From histopathological and clinical points of view, meningiomas are a heterogeneous group of tumors, which are classified into 15 histopathological types with WHO malignancy grades I&#x02013;III [<xref ref-type="bibr" rid="B4">4</xref>].</p><p>Meningiomas was the first solid tumor to be characterized as containing a specific genetic aberration, which is monosomy 22 [<xref ref-type="bibr" rid="B5">5</xref>]. Since then, loss of genetic material from chromosome 22 has been the most consistent aberration, observed in up to 70% of tumors [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. Meningiomas are closely associated with the genetic syndrome neurofibromatosis type-2 (NF2). Approximately 50% of NF2 patients suffer from meningiomas, making them the second most frequent neoplasm associated with this tumor syndrome [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B10">10</xref>]. In 1993, the neurofibromatosis type 2 (<italic>NF2</italic>) tumor suppressor gene was characterized from chromosome 22 [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. Sporadic meningiomas were therefore screened for mutations in the <italic>NF2 </italic>gene, which was found to be frequently inactivated. There is, however, a wide discrepancy in the reported mutation frequency (20&#x02013;60%) [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B18">18</xref>]. In fact, it has been shown that meningiomas may be grouped into tumors with and without mutations in the <italic>NF2 </italic>gene. These groups can also be correlated with histopathological subtypes [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. Tumors with mutations in the <italic>NF2 </italic>gene are often of the transitional or fibrous subtype, commonly with allelic losses on chromosome 22. Tumors without <italic>NF2 </italic>gene mutations are predominantly of the meningothelial subtype, and allelic losses on chromosome 22 are less commonly observed in this subtype. Furthermore, the meningothelial meningiomas are more often located in the anterior parts of the skull base [<xref ref-type="bibr" rid="B19">19</xref>]. Transcriptional silencing of the <italic>NF2 </italic>tumor suppressor by CpG methylation in meningiomas was recently tested by two research groups, but the results were conflicting. Van Tilborg <italic>et al</italic>. reported methylation in 1 out of 21 tumors, whereas Lomas and colleagues reported a higher methylation frequency (23 out of 88 cases) [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref>].</p><p>Despite almost 40 years of cytogenetic and molecular genetic research, the <italic>NF2 </italic>tumor suppressor is still the only specific gene which has been shown to be frequently involved early in the development of meningiomas. There is, however, a general consensus that other not yet characterized loci are important for the development and/or progression of these tumors [<xref ref-type="bibr" rid="B22">22</xref>-<xref ref-type="bibr" rid="B27">27</xref>]. Considering the clinical and histopathological heterogeneity of meningiomas, it is possible that alternative genetic mechanisms underlay its tumorigenesis. There are reports of the loss of chromosome 22 as the primary consistent aberration in meningiomas, in the absence of mutations in the <italic>NF2 </italic>gene. Moreover, young patients with constitutional ring chromosomes and multifocal meningiomas have been characterized. This highlights the possibility of an alternative genetic etiology related to other genes located on chromosome 22 [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B28">28</xref>-<xref ref-type="bibr" rid="B30">30</xref>]. In addition, other sites in the genome have been implicated in meningioma development or progression [<xref ref-type="bibr" rid="B23">23</xref>]. Among these, aberrations of chromosome 1 have been established as the second major genetic factor for the initiation/progression of meningiomas and correlate with increased morbidity [<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B32">32</xref>]. Furthermore, the <italic>NF2 </italic>gene has also been excluded by linkage analysis in one family with multiple meningothelial meningiomas and ependymomas [<xref ref-type="bibr" rid="B33">33</xref>]. These various reports suggest that there exist additional loci contributing to the formation of meningiomas.</p><p>The rationale of this study was to perform a multilevel analysis of mutations that include gene dosage aberrations on chromosome 22, analysis of point mutations in the <italic>NF2 </italic>locus, and profiling of the methylation status within the <italic>NF2 </italic>gene promoter. We also intended to relate our findings from chromosome 22 to the high resolution DNA copy number variation in meningiomas of chromosome 1, which was recently reported [<xref ref-type="bibr" rid="B34">34</xref>].</p></sec><sec><title>Results and discussion</title><p>We analyzed a comprehensive series of sporadic meningiomas on multiple levels, i.e. for presence of "macro-mutations" involving large scale aberrations of 22q using an array-based approach and for "micro-mutations" within the <italic>NF2 </italic>tumor suppressor gene. The latter involved analysis of point mutations within the mRNA encoding part of this gene and within the conserved non-genic (CNGs) sequences, which we have previously defined [<xref ref-type="bibr" rid="B35">35</xref>]. We also comprehensively studied the promoter region of the <italic>NF2 </italic>gene for CpG methylation.</p><sec><title>Chromosome 22 DNA copy number profiling using array-CGH</title><p>We studied 126 sporadic meningioma samples, composing a representative series of tumors operated on at a single hospital in Sweden. All tumor samples studied were analyzed previously using a lower resolution approach [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B36">36</xref>]. The main rationale in this part of the project was to identify tumors possessing gene dosage aberrations of 22q which did not involve the <italic>NF2 </italic>locus. We carried out DNA copy number profiling using array-CGH on a genomic microarray covering chromosome 22. This array, containing 480 measurement points across the sequenced part of this autosome, was developed and validated previously [<xref ref-type="bibr" rid="B37">37</xref>]. Among the samples used for validation of this array was meningioma T24 DNA, which is a well characterized tumor containing a large terminal deletion of 22q and an additional approximately 150 kb biallelic deletion involving <italic>EWSR1</italic>, <italic>GAR22</italic>, <italic>RRP22</italic>, <italic>AP1B1</italic>, <italic>RFPL1 </italic>and <italic>NEFH </italic>genes [<xref ref-type="bibr" rid="B37">37</xref>,<xref ref-type="bibr" rid="B38">38</xref>]. On average, each array-CGH experiment generated ~400 positively scored data points from 22q.</p><p>Table <xref ref-type="table" rid="T1">1</xref> summarizes results obtained from DNA copy number profiling of chromosome 22 and other results, as well as relevant clinical information pertaining to the studied patients. The predominant profile detected in 59 tumors was monosomy 22, which accounted for 47% of meningiomas, and this result is consistent with previous studies [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B36">36</xref>]. The biological consequence of this very common aberration for the affected tumor cells is one copy loss of all genes from 22q. The second category comprised of16 tumors (13%) that were affected by terminal deletions, interstitial deletions and gains, present singly or in combinations (Figure <xref ref-type="fig" rid="F1">1A</xref>). This number is also consistent with previous analysis using a loss of heterozygosity (LOH) approach [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B36">36</xref>]. However, due to a much higher density of data points used in the current analysis, we were able to detect additional aberrations as well as exactly define the breakpoints of all rearrangements in samples which were characterized previously using LOH. Figure <xref ref-type="fig" rid="F1">1A</xref> shows all 16 cases in detail, and Figs. <xref ref-type="fig" rid="F2">2</xref> and <xref ref-type="fig" rid="F3">3</xref> display array-CGH profiles of 7 tumors providing new information. Tumor M64 (Figs. <xref ref-type="fig" rid="F1">1A</xref> and <xref ref-type="fig" rid="F2">2A</xref>) disclosed a previously unknown biallelic deletion affecting the <italic>NF2 </italic>gene. This was the only locus affected by a homozygous deletion in the studied series of tumors, which confirms the importance of the <italic>NF2 </italic>gene in meningioma development. This fibroblastic meningioma has an overall 22q profile consistent with a very large (&#x0003e; 30 Mb) terminal deletion of the long arm of chromosome 22. The second deletion affects only one clone (ID 151) [GenBank: <ext-link ext-link-type="gen" xlink:href="AC005529">AC005529</ext-link>] and specifically targets the <italic>NF2 </italic>gene, thus inactivating its second allele in tumor cells. Another interesting example is fibroblastic meningioma M11, since it displays a terminal and multiple interstitial deletions, all of which are located outside the <italic>NF2 </italic>locus (Figs. <xref ref-type="fig" rid="F1">1A</xref> and <xref ref-type="fig" rid="F2">2E</xref>). Three of these deletions, located towards the telomere of 22q, were previously characterized [<xref ref-type="bibr" rid="B39">39</xref>]. However, current analysis revealed an additional, smaller (~550 kb) deletion, encompassing 5 contiguous clones (ID 85&#x02013;89) [GenBank: <ext-link ext-link-type="gen" xlink:href="U07000">U07000</ext-link>&#x02013;<ext-link ext-link-type="gen" xlink:href="AP000348">AP000348</ext-link>], located on the centromeric side of the <italic>NF2 </italic>locus (Figures <xref ref-type="fig" rid="F1">1A, 1B</xref> and <xref ref-type="fig" rid="F2">2E</xref>). This tumor is intriguing since no additional genetic/epigenetic aberration in the <italic>NF2 </italic>gene could be detected in this sample (see below). The vast majority of copy number aberrations of 22q in meningiomas point to inactivation or a decreased gene dosage. However, in two tumors (M109 and M96, Figs <xref ref-type="fig" rid="F1">1A</xref>, <xref ref-type="fig" rid="F2">2C</xref> and <xref ref-type="fig" rid="F3">3A</xref>) we were able to detect a low copy number gain. For instance, tumor M109 displays a combination of low copy number gain in the centromeric part of 22q and a large terminal deletion (Figure <xref ref-type="fig" rid="F2">2A</xref>). A minimum overlapping region of gain is approximately 3.8 Mb (clone ID 11&#x02013;48) [GenBank: <ext-link ext-link-type="gen" xlink:href="AC006285">AC006285</ext-link> &#x02013; <ext-link ext-link-type="gen" xlink:href="AC007957">AC007957</ext-link>] and is located in 22q11. The importance of these gains for meningioma tumorigenesis is difficult to judge, as they are not frequent events. One possible explanation is that these gains reflect cell-specific chromosomal instability of 22q11, since this region is rich in intra-chromosomal segmental duplications and is prone to rearrangements leading to several genetic disorders.</p><p>All samples displaying aberrations other than monosomy 22 are graphically summarized in Fig <xref ref-type="fig" rid="F1">1A</xref>. This analysis enables the discrimination of several minimal overlapping deleted regions which should be studied further. Two of these regions, named as R1 (~550 kb) and R2 (~250 kb) are small enough to allow for detailed analysis of a limited number of candidate genes (Figs. <xref ref-type="fig" rid="F1">1B</xref> and <xref ref-type="fig" rid="F1">1C</xref>). The <italic>breakpoint cluster region (BCR) </italic>gene is one interesting candidate located in R1. This gene is located at the site of the chromosome 22 breakpoint generating the Philadelphia chromosome (9;22) translocation that creates the <italic>BCR/ABL </italic>fusion gene found in chronic myeloid leukemia and acute myeloid leukemia. The normal <italic>BCR </italic>gene was reported to have a serine/threonine kinase activity [<xref ref-type="bibr" rid="B40">40</xref>]. Another candidate gene located within R1 is the <italic>RGR </italic>oncogene. This gene was originally identified as a fusion protein which can promote tumor development in nude mice, but has also displayed oncogenic properties when not in the fusion form [<xref ref-type="bibr" rid="B41">41</xref>]. The <italic>RGR </italic>gene has frequently been found to be altered in human T-cell malignancies [<xref ref-type="bibr" rid="B42">42</xref>]. The zinc finger protein encoding gene <italic>ZCWCC1</italic>, located within R2, may also be a candidate for further investigation. The relative weakness of the R1 and R2 regions is that they are defined by rare cases with small deletions. There is therefore a possibility that the latter chromosome 22 aberrations are neutral "passenger mutations", with little consequence to tumorigenesis. Yet another apparent, large candidate region is located towards the telomere of 22q, starting from clone ID 390. This segment is affected by hemizygous deletion in all but one (M114) of the studied tumors which disclosed gene copy number imbalances of chromosome 22.</p><p>The third major category of tumors (51 cases, 40%) was composed of samples that did not display detectable changes in gene dosage on 22q (Table <xref ref-type="table" rid="T1">1</xref>, "<bold>N</bold>o <bold>A</bold>berration <bold>D</bold>etected"; NAD) despite the high average resolution (~75 kb per data point). There may be several possible explanations for these results. One possibility is that additional genes on 22q (other than <italic>NF2 </italic>tumor suppressor) are important for meningioma development and these are mutated by alternative mechanisms, such as point mutation or epigenetic silencing. Another explanation might be that this subset of samples involves an alternative tumorigenic pthway which does not involve chromosome 22-located genes.</p><p>The current version of the chromosome 22 array has been supplemented with additional non- 22q-derived genomic clones from other chromosomes, which encompass genes (e.g. <italic>PTCH2A</italic>, <italic>PTCH1B</italic>, <italic>SUFU </italic>and <italic>DAL1 </italic>genes) of potential interest in the fields of meningiomas and brain tumors in general. The complete list of these additional clones is provided in <xref ref-type="supplementary-material" rid="S1">additional file 1</xref>. Table <xref ref-type="table" rid="T1">1</xref> shows the samples in which loss of DNA copy number was detected for some of these loci. The highest rate of loss detected was at the <italic>PTCH2A </italic>locus on 1p34.1, which displayed a rate of loss of 18%. The other loci, namely <italic>DAL-1, PTCH1B</italic>, <italic>SUFU1A </italic>and <italic>SUFU1B</italic>, displayed a level of DNA copy number loss of 6%, 5%, 6% and 6%, respectively. We also detected DNA copy number losses in a number of non-chromosome 22-derived control clones. The most frequently deleted control clones were those derived from chromosomes 1 and 3, suggesting the likely importance of other regions of the genome in meningioma development/progression.</p></sec><sec><title>Mutation analysis of <italic>NF2 </italic>exons and evolutionarily conserved non-genic sequences (CNGs)</title><p>Inactivating micro-mutations in the <italic>NF2 </italic>tumor suppressor gene are found in meningiomas of all histopathological subtypes and malignancy grades and are thought to be an early event in tumorigenesis [<xref ref-type="bibr" rid="B43">43</xref>]. However, large differences (20&#x02013;60%) of mutation frequency in sporadic meningiomas were previously reported [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B18">18</xref>]. Our rationale was to reassess the mutation frequency of <italic>NF2</italic>, especially when combined with very high resolution array-CGH analysis of these tumors. The rationale was also to test the hypothesis that mutations might be located in evolutionarily well conserved non-genic sequences within introns or in the 5' promoter region of the <italic>NF2 </italic>gene, in addition to mutations in the exons. Comparisons of the orthologous genomic sequence from the <italic>NF2 </italic>locus derived from five species (human, baboon, mouse, rat and pufferfish) were previously performed in order to identify CNGs that might be of functional importance for the <italic>NF2 </italic>gene [<xref ref-type="bibr" rid="B35">35</xref>]. The exonic sequence of the <italic>NF2 </italic>gene constitutes ~2.7% of this locus. When applying a threshold of 70% sequence identity over &#x0003e;100 bp of gap-free alignment in comparisons between human and mouse, the resulting level of extra-exonic conservation was 3.8%. We selected CNGs for mutational analysis that displayed a similar level of evolutionarily conservation as the protein coding sequence. In total, 17.5 kb was sequenced in 100 tumors, which included all 17 exons, the highly conserved exon flanking sequences and seven CNGs not contiguous with exons (Figure <xref ref-type="fig" rid="F4">4A</xref>). Four of the CNGs were positioned upstream of exon 1 and the remaining three CNGs were located in introns 1, 4 and 10.</p><p>Thirty-nine alterations were identified in 100 analyzed samples (Tables <xref ref-type="table" rid="T1">1</xref>, <xref ref-type="table" rid="T2">2</xref> and <xref ref-type="table" rid="T3">3</xref>). Fifteen mutations caused frame-shifts, twelve altered the acceptor- or donor-splice sites, nine were nonsense, two were missense and one mutation occurred in the <italic>inter1 </italic>CNG. None of the identified mutations were present in the corresponding peripheral blood DNA. Thirty-five of these mutations were accompanied by a macro-mutation on the other allele, either through monosomy or terminal/interstitial deletions. Overall, we could detect mutations consistent with biallelic inactivation of the <italic>NF2 </italic>tumor suppressor gene in 36% of meningiomas (Table <xref ref-type="table" rid="T3">3</xref>). However, in three cases (M46, M115 and M87) no second inactivating mutation could be identified. Considering what is known to date about the <italic>NF2 </italic>gene mutational spectrum in different tumors, it can be assumed that at least two of the latter three mutations (M46 &#x02013; aberrant splicing and M115 &#x02013; nonsense mutation) are pathogenic. These types of mutations are, however, usually combined with the second inactivating hit on the remaining normal allele of the gene [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B44">44</xref>-<xref ref-type="bibr" rid="B47">47</xref>]. The third aberration is a missense mutation (tumor M87, exon 4, 436 G&#x0003e;A, Val-146-Ile, Table <xref ref-type="table" rid="T1">1</xref>), which is possibly introducing a dysfunction to the N-terminal FERM domain (residues 1&#x02013;302 of the protein, plasma membrane binding domain) of the protein. Merlin/schwannomin provides a link between the cytoskeleton and plasma membrane and interacts with the actin cytoskeleton through binding sites in its FERM domain [<xref ref-type="bibr" rid="B48">48</xref>,<xref ref-type="bibr" rid="B49">49</xref>]. Thus, there exists a possibility of this missense mutation exerting a sufficiently strong dominant negative effect on the protein function, which does not necessitate the presence of the second hit <italic>NF2 </italic>gene inactivating event in this tumor. The three tumors discussed above (M46, M115 and M87) allow us to estimate our false negative detection rate of mutations in the <italic>NF2 </italic>gene. We can speculate that, in at least two and a maximum of three of the studied tumors, we could expect the second hit <italic>NF2 </italic>gene mutation to be present, but we were unable to detect it. Assuming the above reasoning to be correct, our false negative rate of micro-mutation detection is between 5.1 &#x02013; 7.6%.</p><p>In case M22 we identified two tumor-specific micro-mutations, one mutation causing a frame shift in exon 13 introducing a premature stop codon and the second being a mutation in the <italic>inter1 </italic>CNG element. <italic>Inter1 </italic>is situated approximately 15 kb upstream of the <italic>NF2 </italic>gene (Figure <xref ref-type="fig" rid="F4">4A</xref>). It displays sequence conservation between human and pufferfish, which are evolutionarily very distant species [<xref ref-type="bibr" rid="B35">35</xref>], suggesting that <italic>inter1 </italic>may possess functional properties. Details on the exact position of the <italic>inter1 </italic>mutation on chromosome the 22 sequence are shown in Table <xref ref-type="table" rid="T1">1</xref>. The tumor-specific mutation in <italic>inter1 </italic>CNG is one of three changes present in M22, as this tumor also contains monosomy 22. Thus, we may speculate that three hits are affecting the <italic>NF2 </italic>gene. An alternative explanation is that one of these mutations has little consequence to the normal function of the <italic>NF2 </italic>gene.</p></sec><sec><title>Methylation profiling of the <italic>NF2 </italic>promoter region by bisulfite modification followed by pyrosequencing</title><p>Methylation of promoter associated CpG-islands is known as a possible mechanism for inactivation of tumor suppressor genes in a variety of human cancers. It has also been suggested as a mechanism of repressing transcription of the <italic>NF2 </italic>gene in schwannomas [<xref ref-type="bibr" rid="B50">50</xref>] and in meningiomas [<xref ref-type="bibr" rid="B21">21</xref>]. Methylation of other cancer related genes (<italic>GSTP1</italic>, <italic>THBS1</italic>, <italic>CDKN2A</italic>, <italic>CDH1</italic>, <italic>BRCA1</italic>, <italic>p14</italic><sup><italic>ARF </italic></sup>and <italic>RB1</italic>) has also been reported to be associated with malignant progression of meningiomas [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B51">51</xref>,<xref ref-type="bibr" rid="B52">52</xref>]. We used an established method of bisulfite treatment of tumor DNA followed by Pyrosequencing (Biotage, Uppsala, Sweden) which allows detection and semi-quantitative estimation of the degree of methylation at the selected CpGs [<xref ref-type="bibr" rid="B53">53</xref>,<xref ref-type="bibr" rid="B54">54</xref>]. Two overlapping PCR products of 339 bp and 550 bp covered ~750 bp of the upstream promoter region, the first exon and approximately 70 bp of intron 1, immediately downstream of the first exon (Figure <xref ref-type="fig" rid="F4">4B</xref>). These two products were Pyrosequenced with 8 sequencing primers. In total, 40 CpG sites were sequenced, between positions -591 and +166 bp (position +1 refers to transcriptional start site). This analysis allowed interrogation of up to 11 CpG sites per assay, distributed over 79 bp and with a maximum of 60 dispensations of nucleotides (<xref ref-type="supplementary-material" rid="S2">additional file 2</xref>). Methylation was identified in only one tumor sample (M104), at a single CpG site at position +120, in ~40% of DNA molecules in this tumor (Figure <xref ref-type="fig" rid="F4">4B</xref>). Kino <italic>et al</italic>. reported a 70 bp region (-591 to -522) essential for <italic>NF2 </italic>expression in schwannomas [<xref ref-type="bibr" rid="B50">50</xref>]. Three CpG sites within this region (at positions -591, -586 and -581) appeared to be of particular importance for silencing of the <italic>NF2 </italic>gene upon methylation in schwannomas. We paid particular attention to these CpG sites but no methylation was detected. In summary, upon comprehensive analysis of 40 CpG sites, we conclude that methylation does not play a major role in the silencing of the <italic>NF2 </italic>gene in meningiomas. These results are in accordance with a report by van Tilborg <italic>et al </italic>[<xref ref-type="bibr" rid="B20">20</xref>] although contradicting the results from Lomas <italic>et al</italic>. [<xref ref-type="bibr" rid="B21">21</xref>].</p></sec><sec><title>Summary of macro- and micro-mutations on chromosomes 22 and 1 in meningiomas</title><p>We observed pronounced differences of the <italic>NF2 </italic>gene mutation frequency between different histopathological subtypes of meningiomas (Table <xref ref-type="table" rid="T3">3</xref>). There was a clear trend towards an increased frequency of the biallelic <italic>NF2 </italic>gene inactivation in meningothelial, transitional and fibroblastic subtypes which were 6 out of 33 tumors (18%), 12 out of 31 tumors (39%) and 11 out of 21 tumors (52%), respectively. Based on these results, we may speculate that the biallelic inactivation of the <italic>NF2 </italic>gene is not as important for the development of the meningothelial subtype of meningioma, when compared to the transitional and fibroblastic tumors. A related trend was even more pronounced, when the frequencies of large chromosome 22 deletions were correlated to the three above mentioned histopathological subtypes of meningioma. The presence of large hemizygous deletions showed marked differences between the meningothelial, transitional and fibroblastic subtypes, comprising 13 out of 33 cases (39%), 20 out of 31 cases (65%) and 19 out of 21 cases (90%), respectively. It should be stressed here that 15 out of 19 fibroblastic meningiomas, which displayed gene dosage imbalances on 22q, were monosomy 22 cases. The three remaining tumors (M64, M32, and M114) all showed a minimum loss of 18 Mb of 22q. It may thus be hypothesized that one copy loss of genes located within the 18 Mb on 22q is important for generation of the fibroblastic phenotype of cells.</p><p>More than half (61%) of the meningothelial cases were among the category of tumors with both chromosome 22 copies retained. One possible explanation for this finding is that meningothelial tumors more frequently harbor mutations in additional genes that are located outside chromosome 22. Our results correlate well with previous studies by Wellenreuther <italic>et al</italic>. [<xref ref-type="bibr" rid="B15">15</xref>] as well as with Evans and colleagues [<xref ref-type="bibr" rid="B17">17</xref>] that identified <italic>NF2 </italic>gene mutations in 4/26 (15%) and 1/20 (5%) of meningothelial tumors. The above results from DNA level analysis are supported by analysis of merlin/schwannomin protein expression, which show normal expression in the greater part of meningothelial tumors, but severely reduced expression levels in the majority of fibrous and transitional meningiomas [<xref ref-type="bibr" rid="B55">55</xref>-<xref ref-type="bibr" rid="B57">57</xref>]. Furthermore, correlation between tumor localization and histological subtype was previously reported. The majority of meningiomas with no chromosome 22 aberrations were localized in the anterior skull base and were predominantly meningothelial [<xref ref-type="bibr" rid="B19">19</xref>]. Taken together, these results might suggest that cellular origin plays a role in the genetic pathways which are operative during tumor formation of meningiomas. In the context of our results from chromosome 22, it is interesting to correlate this to the data obtained from chromosome 1, as genetic aberrations affecting these two autosomes are the most frequent genetic abnormalities in meningiomas [<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B36">36</xref>]. Furthermore, aberrations of chromosome 1 are also related to recurrence-free survival from the disease [<xref ref-type="bibr" rid="B31">31</xref>]. We have recently completed a high resolution analysis of chromosome 1 using the same tumor series [<xref ref-type="bibr" rid="B34">34</xref>] and 49 of the samples were studied with similar resolution on both chromosomes (Table <xref ref-type="table" rid="T1">1</xref>). There is a strong relationship between changes on both chromosomes, with 67% of samples showing concurrent aberrations. These results clearly indicate the need for a genome-wide and high-resolution array-based characterization of chromosomal aberrations in meningiomas.</p></sec></sec><sec><title>Conclusion</title><p>One objective of this study was to identify the maximum number of tumors displaying copy number aberrations of 22q not encompassing the <italic>NF2 </italic>locus. From the category of tumors displaying terminal- and interstitial-deletions we identified at least two minimal overlapping candidate regions outside the <italic>NF2 </italic>locus. These regions allow analysis of a limited number of candidate genes. Interesting candidates in these regions include the <italic>BCR </italic>gene, implicated in chronic myeloid leukemia and acute myeloid leukemia; the <italic>RGR </italic>oncogene involved in RAS-signaling [<xref ref-type="bibr" rid="B58">58</xref>] and found to be altered in human T-cell malignancies [<xref ref-type="bibr" rid="B42">42</xref>]; and the zinc finger protein encoding gene <italic>ZCWCC1</italic>. One additional candidate region starts at clone ID 390 and extends toward the telomere (Fig <xref ref-type="fig" rid="F1">1A</xref>). This segment is hemizygously deleted in all but one (M114) of the studied tumors with 22q gene copy number imbalances.</p><p>We assessed the point mutation frequency of <italic>NF2 </italic>in combination with array-CGH of 22q. The rationale was to test the hypothesis that mutations also may be located in evolutionarily well conserved non-genic sequences within introns or in the 5' promoter region, in addition to mutations in the exons. We identified 39 point mutations in 100 tumors. In one single case (M22), there were three tumor-specific mutations detected; a point mutation in the CNG <italic>inter1</italic>, a nonsense mutation in exon 13 and monosomy 22. <italic>Inter1 </italic>displays sequence conservation between human and pufferfish, suggesting that it may possess functional properties. However, the fact that the <italic>inter1 </italic>mutation represented one out of three genetic alterations in this tumor, and that we only identified a single mutation in one CNG, suggests that this is not a major mechanism for inactivation of the <italic>NF2 </italic>gene. We also analyzed the methylation status of <italic>NF2 </italic>promoter associated CpGs in order to examine if this mechanism is associated with repressing <italic>NF2 </italic>transcription in sporadic meningiomas. We identified methylation in only one tumor sample (M104), at a single CpG site (Figure <xref ref-type="fig" rid="F4">4B</xref>). Thus, we conclude that methylation is unlikely to play a major role in silencing of the <italic>NF2 </italic>gene in meningioma.</p><p>Profound differences in mutation frequency were observed between various histopathological subtypes of tumors. There was a considerably higher frequency of biallelic <italic>NF2 </italic>inactivation in fibroblastic (52%) compared to meningothelial (18%) tumors. The presence of 22q copy number imbalances were also more common in the fibroblastic (86%) compared to the meningothelial (39%) subtype. Thus, inactivation of <italic>NF2 </italic>combined with the presence of macro-mutation on 22q, might not be as important for the development of the meningothelial subtype, as opposed to the fibroblastic form.</p><p>Chromosome 1 genetic abnormalities are frequently observed in meningiomas [<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B36">36</xref>]. Forty-nine of the samples studied here were also previously analyzed for gene dosage aberrations on chromosome 1 by array-CGH [<xref ref-type="bibr" rid="B34">34</xref>]. We observed a strong correlation between changes on both chromosomes, with 67% of samples showing concurrent aberrations. A genome-wide and high-resolution copy number analysis could contribute to identify additional genetic alterations involved in tumor development, especially for the meningothelial subtype, which does not commonly display <italic>NF2 </italic>and 22q alterations.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patient samples</title><p>Tumor tissue and matched samples of peripheral blood were collected and DNA was isolated using standard methods [<xref ref-type="bibr" rid="B59">59</xref>]. Samples were obtained from the Dept. of Neurosurgery, Karolinska Hospital, Stockholm, Sweden. All analyzed tumor samples were reported previously in various studies [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B36">36</xref>]. Ethical approval was granted from the Research Ethics Committee, Faculty of Medicine, Uppsala University. Copy number profiling of chromosome 22 was performed on 126 sporadic meningiomas and this sample set comprised 39 meningothelial, 38 transitional, 28 fibroblastic, 9 anaplastic, 6 psammomatous, 1 angiomatous and 5 tumors of unclassified histopathological subtype. For the analysis for point mutations and methylation in the <italic>NF2 </italic>gene promoter, we used a subset of 100 tumor DNA samples (Table <xref ref-type="table" rid="T1">1</xref> and <xref ref-type="supplementary-material" rid="S3">additional file 3</xref>).</p></sec><sec><title>DNA copy number profiling using the chromosome 22 genomic microarray</title><p>The genomic microarray used to assess DNA copy number status of chromosome 22 has been described previously [<xref ref-type="bibr" rid="B37">37</xref>]. In brief, 480 genomic clones derived from the minimal tiling path of chromosome 22, 8 control clones from chromosome X and 30 non-chromosome 22 autosomal control clones were isolated and grown in bacterial cultures overnight. The clone DNA (cosmid, fosmid, BAC and PAC) was purified using Qiagen kits and quantified using the picoGreen assay (Molecular Probes, Inc., Eugene, OR). All clone DNA were verified using STS PCR. The prepared clone DNA stock was amplified by DOP-PCR [<xref ref-type="bibr" rid="B60">60</xref>]. A second round of PCR on the DOP-PCR products using an amino linked universal primer was performed and amplification products were printed in quadruplicate on CodeLink&#x02122; slides (GE Healthcare, UK). Protocols used for the hybridization and washing procedures have been previously described [<xref ref-type="bibr" rid="B37">37</xref>,<xref ref-type="bibr" rid="B61">61</xref>]. Image capture and analysis was performed using the axon 4000B Scanner and GenePix 6 image analysis software. For all clones on the array the average, standard deviation and coefficient of variation (CV) for each of the 4 replicas was calculated. Clones displaying a CV above 5% between a minimum of 3 replica spots were discarded from further analysis. Array-CGH profiles are plotted in Microsoft Excel with the clone IDs on the X-axis and the normalized fluorescent ratio intensities on the y-axis. The average fluorescent ratio value for a given set of continuous clones on the array is referred to as the <bold>A</bold>verage <bold>N</bold>ormalized <bold>I</bold>nter <bold>L</bold>ocus <bold>F</bold>luorescence <bold>R</bold>atio or ANILFR value.</p></sec><sec><title>PCR and sequencing</title><p>Exons and conserved non-genic sequences (CNGs) in the <italic>NF2 </italic>locus were PCR amplified from genomic DNA derived from one hundred sporadic meningiomas, with customized primers using Ampli Taq Gold (Applied Biosystems) (primer list in <xref ref-type="supplementary-material" rid="S4">Additional file 4</xref>). Peripheral blood DNA from phenotypically normal control persons was also PCR amplified and sequenced for CNGs in which mutations were observed. PCR fragments were purified by Exosapit (GE Healthcare, UK) digestion prior to sequencing. Sequencing of amplicons was performed with customized nested primers using ET Terminator (GE Healthcare, UK) and Big Dye v.3.1 (Applied Biosystems) sequencing chemistries, and ethanol precipitated according to standard protocol [<xref ref-type="bibr" rid="B59">59</xref>]. Electrophoresis and fluorescent detection was carried out on Megabace 1000 (GE Healthcare, UK) and ABI 3700 (Applied Biosystems) capillary sequencing machines. Processing and analysis of sequencing data was performed using the Staden package [<xref ref-type="bibr" rid="B62">62</xref>].</p></sec><sec><title>Methylation profiling by pyrosequencing of bisulfite treated DNA</title><p>Pyrosequencing (Biotage, Uppsala, Sweden) was used as method for detection of methylation of cytosines situated 5'of a guanine [<xref ref-type="bibr" rid="B53">53</xref>]. Briefly, the DNA was bisulfite treated using EZ-96 DNA methylation kit (Zymo research, Orange, CA, USA) for conversion of unmethylated cytosines into uracils. In the subsequent PCR uracil amplifies as thymidine. Methylated cytosines remain unchanged after treatment. Cytosines not followed by a guanine are not methylated and will therefore be converted to a thymidine after bisulfite treatment and PCR. These thymidines were used as internal controls for the completeness of bisulfite treatment. Human genomic DNA was methylated in vitro by the CpG methylase <italic>M. Sss I </italic>and used as positive controls for detection of methylation. Bisulfite treated DNA were amplified in a 50 &#x003bc;l reaction using Platinum Taq DNA polymerase (Invitrogen Life Technologies, Carlsbad, CA, USA) according to manufacturers protocol. Primers for amplification and sequencing were custom designed using PSQ assay design software (Biotage, Uppsala, Sweden). Data of primers used for amplification and sequencing, as well as the nucleotide sequence analyzed and the dispensation order of nucleotides during sequencing is shown in <xref ref-type="supplementary-material" rid="S2">Additional file 2</xref>. One PCR primer in each pair was biotinylated for conversion of the PCR product to a single stranded template. The cycling condition used were: 94&#x000b0;C for 3 minutes, followed by 20 cycles of 94&#x000b0;C for 20 seconds, 65&#x000b0;C minus 0.5&#x000b0;C/cycle for 20 seconds, 72&#x000b0;C for 1 minute, followed by 40 cycles of 94&#x000b0;C for 20 seconds, 55&#x000b0;C for 20 seconds, 72&#x000b0;C for 1 minute and finally 72&#x000b0;C for 10 minutes. 45 &#x003bc;l of PCR product was used for the Pyrosequencing reaction. Sequencing was performed on a PSQ 96MA system with PSQ Gold reagent kit (Biotage, Uppsala, Sweden) according to manufacturer's protocol. Pyro Q-CpG software (Biotage, Uppsala, Sweden) was used for data analysis.</p></sec></sec><sec><title>Authors' contributions</title><p>CMH: participated in the overall study design; performed mutation analysis experiments, methylation analysis experiments, array-CGH experiments; analyzed results and drafted the manuscript. PB: participated in the array-CGH study design, performed array-CGH experiments, data analysis and drafted the manuscript. GG: participated in the study design of the mutation screening part and analysis of sequencing data. AP: participated in the methylation analysis study design. ARH: performed mutation screening and analysis of sequencing data. KM: performed printing of the micro-array. CJ: participated in the preparations of the microarray. TM: provided with tumor and blood samples, provided clinical data of all patients. JPD: intellectual input in the overall study design, drafted the manuscript and generated financial support. All authors read and approved the final manuscript.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p>Table summarizing DNA copy number changes in the additional subset of 26 sporadic meningiomas not studied for NF2 gene point mutations or NF2 promoter methylation status.</p></caption><media xlink:href="1471-2164-8-16-S1.pdf" mimetype="application" mime-subtype="pdf"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S2"><caption><title>Additional file 2</title><p>Table summarizing primers used for PCR amplification and sequencing of the NF2 gene.</p></caption><media xlink:href="1471-2164-8-16-S2.pdf" mimetype="application" mime-subtype="pdf"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S3"><caption><title>Additional file 3</title><p>Table summarizing primer pairs used for amplification of bisulfite treated DNA, sequencing primers, analyzed sequences and dispensation order.</p></caption><media xlink:href="1471-2164-8-16-S3.pdf" mimetype="application" mime-subtype="pdf"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S4"><caption><title>Additional file 4</title><p>List of non-22q-derived genomic clones that encompass genes of potential interest in tumor formation/progression.</p></caption><media xlink:href="1471-2164-8-16-S4.pdf" mimetype="application" mime-subtype="pdf"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>This work was supported by grants from the U.S. Army Medical Research and Materiel Command (award no. W81XWH-04-1-0269), the Wallenberg Consortium North, the Swedish Cancer Foundation, the Swedish Research Council and Uppsala University to JPD. Chris Partridge is greatly acknowledged for proofreading the manuscript.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Russel</surname><given-names>DS</given-names></name><name><surname>Rubinstein</surname><given-names>LJ</given-names></name></person-group><source>Pathology of the tumors of the nervous system</source><year>1989</year><edition>Fifth edition</edition><publisher-name>London , Edward Arnold</publisher-name></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rausing</surname><given-names>A</given-names></name><name><surname>Ybo</surname><given-names>W</given-names></name><name><surname>Stenflo</surname><given-names>J</given-names></name></person-group><article-title>Intracranial meningioma--a population study of ten years</article-title><source>Acta Neurol Scand</source><year>1970</year><volume>46</volume><fpage>102</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">5412623</pub-id></citation></ref><ref id="B3"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Kepes</surname><given-names>JJ</given-names></name></person-group><source>Meningiomas; biology, pathology and differential diagnosis</source><year>1982</year><publisher-name>New York , Masson Publishing, Inc. USA</publisher-name></citation></ref><ref id="B4"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Kleihues</surname><given-names>P</given-names></name><name><surname>Cavenee</surname><given-names>WK</given-names></name></person-group><source>Pathology and Genetics. Tumors of the Nervous System.</source><year>2000</year><publisher-name>Lyon , IARC Press</publisher-name></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zang</surname><given-names>KD</given-names></name><name><surname>Singer</surname><given-names>H</given-names></name></person-group><article-title>Chromosomal consitution of meningiomas</article-title><source>Nature</source><year>1967</year><volume>216</volume><fpage>84</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">6050684</pub-id><pub-id pub-id-type="doi">10.1038/216084a0</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seizinger</surname><given-names>BR</given-names></name><name><surname>de la Monte</surname><given-names>S</given-names></name><name><surname>Atkins</surname><given-names>L</given-names></name><name><surname>Gusella</surname><given-names>JF</given-names></name><name><surname>Martuza</surname><given-names>RL</given-names></name></person-group><article-title>Molecular genetic approach to human meningioma: loss of genes on chromosome 22</article-title><source>Proc Natl Acad Sci U S A</source><year>1987</year><volume>84</volume><fpage>5419</fpage><lpage>5423</lpage><pub-id pub-id-type="pmid">3037550</pub-id><pub-id pub-id-type="doi">10.1073/pnas.84.15.5419</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruttledge</surname><given-names>MH</given-names></name><name><surname>Sarrazin</surname><given-names>J</given-names></name><name><surname>Rangaratnam</surname><given-names>S</given-names></name><name><surname>Phelan</surname><given-names>CM</given-names></name><name><surname>Twist</surname><given-names>E</given-names></name><name><surname>Merel</surname><given-names>P</given-names></name><name><surname>Delattre</surname><given-names>O</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Nordenskjold</surname><given-names>M</given-names></name><name><surname>Collins</surname><given-names>VP</given-names></name><name><surname>Dumanski</surname><given-names>JP</given-names></name><name><surname>Rouleau</surname><given-names>GA</given-names></name></person-group><article-title>Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas</article-title><source>Nat Genet</source><year>1994</year><volume>6</volume><fpage>180</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">8162072</pub-id><pub-id pub-id-type="doi">10.1038/ng0294-180</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>DG</given-names></name><name><surname>Huson</surname><given-names>SM</given-names></name><name><surname>Donnai</surname><given-names>D</given-names></name><name><surname>Neary</surname><given-names>W</given-names></name><name><surname>Blair</surname><given-names>V</given-names></name><name><surname>Teare</surname><given-names>D</given-names></name><name><surname>Newton</surname><given-names>V</given-names></name><name><surname>Strachan</surname><given-names>T</given-names></name><name><surname>Ramsden</surname><given-names>R</given-names></name><name><surname>Harris</surname><given-names>R</given-names></name></person-group><article-title>A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity</article-title><source>J Med Genet</source><year>1992</year><volume>29</volume><fpage>841</fpage><lpage>846</lpage><pub-id pub-id-type="pmid">1479598</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>DG</given-names></name><name><surname>Huson</surname><given-names>SM</given-names></name><name><surname>Donnai</surname><given-names>D</given-names></name><name><surname>Neary</surname><given-names>W</given-names></name><name><surname>Blair</surname><given-names>V</given-names></name><name><surname>Newton</surname><given-names>V</given-names></name><name><surname>Harris</surname><given-names>R</given-names></name></person-group><article-title>A clinical study of type 2 neurofibromatosis</article-title><source>Q J Med</source><year>1992</year><volume>84</volume><fpage>603</fpage><lpage>618</lpage><pub-id pub-id-type="pmid">1484939</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parry</surname><given-names>DM</given-names></name><name><surname>Eldridge</surname><given-names>R</given-names></name><name><surname>Kaiser-Kupfer</surname><given-names>MI</given-names></name><name><surname>Bouzas</surname><given-names>EA</given-names></name><name><surname>Pikus</surname><given-names>A</given-names></name><name><surname>Patronas</surname><given-names>N</given-names></name></person-group><article-title>Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity</article-title><source>Am J Med Genet</source><year>1994</year><volume>52</volume><fpage>450</fpage><lpage>461</lpage><pub-id pub-id-type="pmid">7747758</pub-id><pub-id pub-id-type="doi">10.1002/ajmg.1320520411</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rouleau</surname><given-names>GA</given-names></name><name><surname>Merel</surname><given-names>P</given-names></name><name><surname>Lutchman</surname><given-names>M</given-names></name><name><surname>Sanson</surname><given-names>M</given-names></name><name><surname>Zucman</surname><given-names>J</given-names></name><name><surname>Marineau</surname><given-names>C</given-names></name><name><surname>Hoang-Xuan</surname><given-names>K</given-names></name><name><surname>Demczuk</surname><given-names>S</given-names></name><name><surname>Desmaze</surname><given-names>C</given-names></name><name><surname>Plougastel</surname><given-names>B</given-names></name><name><surname>Pulst</surname><given-names>SM</given-names></name><name><surname>Lenoir</surname><given-names>G</given-names></name><name><surname>Bijlsma</surname><given-names>E</given-names></name><name><surname>Fashold</surname><given-names>R</given-names></name><name><surname>Dumanski</surname><given-names>J</given-names></name><name><surname>Jong</surname><given-names>P</given-names></name><name><surname>Parry</surname><given-names>D</given-names></name><name><surname>Eldrige</surname><given-names>R</given-names></name><name><surname>Aurias</surname><given-names>A</given-names></name><name><surname>Delattre</surname><given-names>O</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name></person-group><article-title>Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2</article-title><source>Nature</source><year>1993</year><volume>363</volume><fpage>515</fpage><lpage>521</lpage><pub-id pub-id-type="pmid">8379998</pub-id><pub-id pub-id-type="doi">10.1038/363515a0</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trofatter</surname><given-names>JA</given-names></name><name><surname>MacCollin</surname><given-names>MM</given-names></name><name><surname>Rutter</surname><given-names>JL</given-names></name><name><surname>Murrell</surname><given-names>JR</given-names></name><name><surname>Duyao</surname><given-names>MP</given-names></name><name><surname>Parry</surname><given-names>DM</given-names></name><name><surname>Eldridge</surname><given-names>R</given-names></name><name><surname>Kley</surname><given-names>N</given-names></name><name><surname>Menon</surname><given-names>AG</given-names></name><name><surname>Pulaski</surname><given-names>K</given-names></name><name><surname>Haase</surname><given-names>VH</given-names></name><name><surname>Ambrose</surname><given-names>CM</given-names></name><name><surname>Munroe</surname><given-names>D</given-names></name><name><surname>Bove</surname><given-names>C</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Martuza</surname><given-names>RL</given-names></name><name><surname>MacDonald</surname><given-names>ME</given-names></name><name><surname>Seizinger</surname><given-names>BR</given-names></name><name><surname>Short</surname><given-names>MP</given-names></name><name><surname>Buckler</surname><given-names>AJ</given-names></name><name><surname>Gusella</surname><given-names>JF</given-names></name></person-group><article-title>A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor</article-title><source>Cell</source><year>1993</year><volume>75</volume><fpage>826</fpage><pub-id pub-id-type="pmid">8242753</pub-id><pub-id pub-id-type="doi">10.1016/0092-8674(93)90501-G</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lekanne Deprez</surname><given-names>RH</given-names></name><name><surname>Bianchi</surname><given-names>AB</given-names></name><name><surname>Groen</surname><given-names>NA</given-names></name><name><surname>Seizinger</surname><given-names>BR</given-names></name><name><surname>Hagemeijer</surname><given-names>A</given-names></name><name><surname>van Drunen</surname><given-names>E</given-names></name><name><surname>Bootsma</surname><given-names>D</given-names></name><name><surname>Koper</surname><given-names>JW</given-names></name><name><surname>Avezaat</surname><given-names>CJ</given-names></name><name><surname>Kley</surname><given-names>N</given-names></name><name><surname>Zwarthoff</surname><given-names>EC</given-names></name></person-group><article-title>Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas</article-title><source>Am J Hum Genet</source><year>1994</year><volume>54</volume><fpage>1022</fpage><lpage>1029</lpage><pub-id pub-id-type="pmid">7911002</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Papi</surname><given-names>L</given-names></name><name><surname>De Vitis</surname><given-names>LR</given-names></name><name><surname>Vitelli</surname><given-names>F</given-names></name><name><surname>Ammannati</surname><given-names>F</given-names></name><name><surname>Mennonna</surname><given-names>P</given-names></name><name><surname>Montali</surname><given-names>E</given-names></name><name><surname>Bigozzi</surname><given-names>U</given-names></name></person-group><article-title>Somatic mutations in the neurofibromatosis type 2 gene in sporadic meningiomas</article-title><source>Hum Genet</source><year>1995</year><volume>95</volume><fpage>347</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">7868131</pub-id><pub-id pub-id-type="doi">10.1007/BF00225206</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wellenreuther</surname><given-names>R</given-names></name><name><surname>Kraus</surname><given-names>JA</given-names></name><name><surname>Lenartz</surname><given-names>D</given-names></name><name><surname>Menon</surname><given-names>AG</given-names></name><name><surname>Schramm</surname><given-names>J</given-names></name><name><surname>Louis</surname><given-names>DN</given-names></name><name><surname>Ramesh</surname><given-names>V</given-names></name><name><surname>Gusella</surname><given-names>JF</given-names></name><name><surname>Wiestler</surname><given-names>OD</given-names></name><name><surname>von Deimling</surname><given-names>A</given-names></name></person-group><article-title>Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma</article-title><source>Am J Pathol</source><year>1995</year><volume>146</volume><fpage>827</fpage><lpage>832</lpage><pub-id pub-id-type="pmid">7717450</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Vitis</surname><given-names>LR</given-names></name><name><surname>Tedde</surname><given-names>A</given-names></name><name><surname>Vitelli</surname><given-names>F</given-names></name><name><surname>Ammannati</surname><given-names>F</given-names></name><name><surname>Mennonna</surname><given-names>P</given-names></name><name><surname>Bigozzi</surname><given-names>U</given-names></name><name><surname>Montali</surname><given-names>E</given-names></name><name><surname>Papi</surname><given-names>L</given-names></name></person-group><article-title>Screening for mutations in the neurofibromatosis type 2 (NF2) gene in sporadic meningiomas</article-title><source>Hum Genet</source><year>1996</year><volume>97</volume><fpage>632</fpage><lpage>637</lpage><pub-id pub-id-type="pmid">8655144</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>JJ</given-names></name><name><surname>Jeun</surname><given-names>SS</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Harwalkar</surname><given-names>JA</given-names></name><name><surname>Shoshan</surname><given-names>Y</given-names></name><name><surname>Cowell</surname><given-names>JK</given-names></name><name><surname>Golubic</surname><given-names>M</given-names></name></person-group><article-title>Molecular alterations in the neurofibromatosis type 2 gene and its protein rarely occurring in meningothelial meningiomas</article-title><source>J Neurosurg</source><year>2001</year><volume>94</volume><fpage>111</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">11147878</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>DG</given-names></name><name><surname>Watson</surname><given-names>C</given-names></name><name><surname>King</surname><given-names>A</given-names></name><name><surname>Wallace</surname><given-names>AJ</given-names></name><name><surname>Baser</surname><given-names>ME</given-names></name></person-group><article-title>Multiple meningiomas: differential involvement of the NF2 gene in children and adults</article-title><source>J Med Genet</source><year>2005</year><volume>42</volume><fpage>45</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">15635074</pub-id><pub-id pub-id-type="doi">10.1136/jmg.2004.023705</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kros</surname><given-names>J</given-names></name><name><surname>de Greve</surname><given-names>K</given-names></name><name><surname>van Tilborg</surname><given-names>A</given-names></name><name><surname>Hop</surname><given-names>W</given-names></name><name><surname>Pieterman</surname><given-names>H</given-names></name><name><surname>Avezaat</surname><given-names>C</given-names></name><name><surname>Lekanne Dit Deprez</surname><given-names>R</given-names></name><name><surname>Zwarthoff</surname><given-names>E</given-names></name></person-group><article-title>NF2 status of meningiomas is associated with tumour localization and histology</article-title><source>J Pathol</source><year>2001</year><volume>194</volume><fpage>367</fpage><lpage>372</lpage><pub-id pub-id-type="pmid">11439370</pub-id><pub-id pub-id-type="doi">10.1002/path.909</pub-id></citation></ref><ref id="B20"><citation citation-type="other"><person-group person-group-type="author"><name><surname>van Tilborg</surname><given-names>AA</given-names></name><name><surname>Morolli</surname><given-names>B</given-names></name><name><surname>Giphart-Gassler</surname><given-names>M</given-names></name><name><surname>de Vries</surname><given-names>A</given-names></name><name><surname>van Geenen</surname><given-names>DA</given-names></name><name><surname>Lurkin</surname><given-names>I</given-names></name><name><surname>Kros</surname><given-names>JM</given-names></name><name><surname>Zwarthoff</surname><given-names>EC</given-names></name></person-group><article-title>Lack of genetic and epigenetic changes in meningiomas without NF2 loss</article-title><source>J Pathol</source><year>2005</year></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><collab>21</collab><name><surname>Lomas</surname><given-names>J</given-names></name><name><surname>Bello</surname><given-names>MJ</given-names></name><name><surname>Arjona</surname><given-names>D</given-names></name><name><surname>Alonso</surname><given-names>ME</given-names></name><name><surname>Martinez-Glez</surname><given-names>V</given-names></name><name><surname>Lopez-Marin</surname><given-names>I</given-names></name><name><surname>Aminoso</surname><given-names>C</given-names></name><name><surname>de Campos</surname><given-names>JM</given-names></name><name><surname>Isla</surname><given-names>A</given-names></name><name><surname>Vaquero</surname><given-names>J</given-names></name><name><surname>Rey</surname><given-names>JA</given-names></name></person-group><article-title>Genetic and epigenetic alteration of the NF2 gene in sporadic meningiomas</article-title><source>Genes Chromosomes Cancer</source><year>2005</year><volume>42</volume><fpage>314</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">15609345</pub-id><pub-id pub-id-type="doi">10.1002/gcc.20141</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dumanski</surname><given-names>JP</given-names></name><name><surname>Carlbom</surname><given-names>E</given-names></name><name><surname>Collins</surname><given-names>VP</given-names></name><name><surname>Nordenskjold</surname><given-names>M</given-names></name></person-group><article-title>Deletion mapping of a locus on human chromosome 22 involved in the oncogenesis of meningioma</article-title><source>Proc Natl Acad Sci U S A</source><year>1987</year><volume>84</volume><fpage>9275</fpage><lpage>9279</lpage><pub-id pub-id-type="pmid">2892198</pub-id><pub-id pub-id-type="doi">10.1073/pnas.84.24.9275</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lindblom</surname><given-names>A</given-names></name><name><surname>Ruttledge</surname><given-names>M</given-names></name><name><surname>Collins</surname><given-names>VP</given-names></name><name><surname>Nordenskjold</surname><given-names>M</given-names></name><name><surname>Dumanski</surname><given-names>JP</given-names></name></person-group><article-title>Chromosomal deletions in anaplastic meningiomas suggest multiple regions outside chromosome 22 as important in tumor progression</article-title><source>Int J Cancer</source><year>1994</year><volume>56</volume><fpage>354</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">8314321</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>DX</given-names></name><name><surname>Banerjee</surname><given-names>R</given-names></name><name><surname>Scheithauer</surname><given-names>BW</given-names></name><name><surname>Lohse</surname><given-names>CM</given-names></name><name><surname>Kleinschmidt-Demasters</surname><given-names>BK</given-names></name><name><surname>Perry</surname><given-names>A</given-names></name></person-group><article-title>Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: diagnostic and prognostic implications</article-title><source>J Neuropathol Exp Neurol</source><year>2001</year><volume>60</volume><fpage>628</fpage><lpage>636</lpage><pub-id pub-id-type="pmid">11398839</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buschges</surname><given-names>R</given-names></name><name><surname>Ichimura</surname><given-names>K</given-names></name><name><surname>Weber</surname><given-names>RG</given-names></name><name><surname>Reifenberger</surname><given-names>G</given-names></name><name><surname>Collins</surname><given-names>VP</given-names></name></person-group><article-title>Allelic gain and amplification on the long arm of chromosome 17 in anaplastic meningiomas</article-title><source>Brain Pathol</source><year>2002</year><volume>12</volume><fpage>145</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">11958368</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>A</given-names></name><name><surname>Banerjee</surname><given-names>R</given-names></name><name><surname>Lohse</surname><given-names>CM</given-names></name><name><surname>Kleinschmidt-DeMasters</surname><given-names>BK</given-names></name><name><surname>Scheithauer</surname><given-names>BW</given-names></name></person-group><article-title>A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas</article-title><source>Brain Pathol</source><year>2002</year><volume>12</volume><fpage>183</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">11958372</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sulman</surname><given-names>EP</given-names></name><name><surname>White</surname><given-names>PS</given-names></name><name><surname>Brodeur</surname><given-names>GM</given-names></name></person-group><article-title>Genomic annotation of the meningioma tumor suppressor locus on chromosome 1p34</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><fpage>1014</fpage><lpage>1020</lpage><pub-id pub-id-type="pmid">14749765</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1206623</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arinami</surname><given-names>T</given-names></name><name><surname>Kondo</surname><given-names>I</given-names></name><name><surname>Hamaguchi</surname><given-names>H</given-names></name><name><surname>Nakajima</surname><given-names>S</given-names></name></person-group><article-title>Multifocal meningiomas in a patient with a constitutional ring chromosome 22</article-title><source>J Med Genet</source><year>1986</year><volume>23</volume><fpage>178</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">3712397</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Petrella</surname><given-names>R</given-names></name><name><surname>Levine</surname><given-names>S</given-names></name><name><surname>Wilmot</surname><given-names>PL</given-names></name><name><surname>Ashar</surname><given-names>KD</given-names></name><name><surname>Casamassima</surname><given-names>AC</given-names></name><name><surname>Shapiro</surname><given-names>LRR</given-names></name></person-group><article-title>Multiple meningiomas in a patient with constitutional ring chromosome 22</article-title><source>Am J Med Genet</source><year>1993</year><volume>47</volume><fpage>184</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">8213904</pub-id><pub-id pub-id-type="doi">10.1002/ajmg.1320470211</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akagi</surname><given-names>K</given-names></name><name><surname>Kurahashi</surname><given-names>H</given-names></name><name><surname>Arita</surname><given-names>N</given-names></name><name><surname>Hayakawa</surname><given-names>T</given-names></name><name><surname>Monden</surname><given-names>M</given-names></name><name><surname>Mori</surname><given-names>T</given-names></name><name><surname>Takai</surname><given-names>S</given-names></name><name><surname>Nishisho</surname><given-names>I</given-names></name></person-group><article-title>Deletion mapping of the long arm of chromosome 22 in human meningiomas</article-title><source>Int J Cancer</source><year>1995</year><volume>60</volume><fpage>178</fpage><lpage>182</lpage><pub-id pub-id-type="pmid">7829212</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sulman</surname><given-names>EP</given-names></name><name><surname>Dumanski</surname><given-names>JP</given-names></name><name><surname>White</surname><given-names>PS</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Maris</surname><given-names>JM</given-names></name><name><surname>Mathiesen</surname><given-names>T</given-names></name><name><surname>Bruder</surname><given-names>C</given-names></name><name><surname>Cnaan</surname><given-names>A</given-names></name><name><surname>Brodeur</surname><given-names>GM</given-names></name></person-group><article-title>Identification of a consistent region of allelic loss on 1p32 in meningiomas: correlation with increased morbidity</article-title><source>Cancer Res</source><year>1998</year><volume>58</volume><fpage>3226</fpage><lpage>3230</lpage><pub-id pub-id-type="pmid">9699646</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ishino</surname><given-names>S</given-names></name><name><surname>Hashimoto</surname><given-names>N</given-names></name><name><surname>Fushiki</surname><given-names>S</given-names></name><name><surname>Date</surname><given-names>K</given-names></name><name><surname>Mori</surname><given-names>T</given-names></name><name><surname>Fujimoto</surname><given-names>M</given-names></name><name><surname>Nakagawa</surname><given-names>Y</given-names></name><name><surname>Ueda</surname><given-names>S</given-names></name><name><surname>Abe</surname><given-names>T</given-names></name><name><surname>Inazawa</surname><given-names>J</given-names></name></person-group><article-title>Loss of material from chromosome arm 1p during malignant progression of meningioma revealed by fluorescent in situ hybridization</article-title><source>Cancer</source><year>1998</year><volume>83</volume><fpage>360</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">9669820</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1097-0142(19980715)83:2&#x0003c;360::AID-CNCR21&#x0003e;3.0.CO;2-Q</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pulst</surname><given-names>SM</given-names></name><name><surname>Rouleau</surname><given-names>GA</given-names></name><name><surname>Marineau</surname><given-names>C</given-names></name><name><surname>Fain</surname><given-names>P</given-names></name><name><surname>Sieb</surname><given-names>JP</given-names></name></person-group><article-title>Familial meningioma is not allelic to neurofibromatosis 2</article-title><source>Neurology</source><year>1993</year><volume>43</volume><fpage>2096</fpage><lpage>2098</lpage><pub-id pub-id-type="pmid">8413972</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buckley</surname><given-names>PG</given-names></name><name><surname>Jarbo</surname><given-names>C</given-names></name><name><surname>Menzel</surname><given-names>U</given-names></name><name><surname>Mathiesen</surname><given-names>T</given-names></name><name><surname>Scott</surname><given-names>C</given-names></name><name><surname>Gregory</surname><given-names>SG</given-names></name><name><surname>Langford</surname><given-names>CF</given-names></name><name><surname>Dumanski</surname><given-names>JP</given-names></name></person-group><article-title>Comprehensive DNA copy number profiling of meningioma using a chromosome 1 tiling path microarray identifies novel candidate tumor suppressor loci</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>2653</fpage><lpage>2661</lpage><pub-id pub-id-type="pmid">15805262</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-3651</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hansson</surname><given-names>CM</given-names></name><name><surname>Ali</surname><given-names>H</given-names></name><name><surname>Bruder</surname><given-names>CE</given-names></name><name><surname>Fransson</surname><given-names>I</given-names></name><name><surname>Kluge</surname><given-names>S</given-names></name><name><surname>Andersson</surname><given-names>B</given-names></name><name><surname>Roe</surname><given-names>BA</given-names></name><name><surname>Menzel</surname><given-names>U</given-names></name><name><surname>Dumanski</surname><given-names>JP</given-names></name></person-group><article-title>Strong conservation of the human NF2 locus based on sequence comparison in five species</article-title><source>Mamm Genome</source><year>2003</year><volume>14</volume><fpage>526</fpage><lpage>536</lpage><pub-id pub-id-type="pmid">12925885</pub-id><pub-id pub-id-type="doi">10.1007/s00335-003-3011-3</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dumanski</surname><given-names>JP</given-names></name><name><surname>Rouleau</surname><given-names>GA</given-names></name><name><surname>Nordenskjold</surname><given-names>M</given-names></name><name><surname>Collins</surname><given-names>VP</given-names></name></person-group><article-title>Molecular genetic analysis of chromosome 22 in 81 cases of meningioma</article-title><source>Cancer Res</source><year>1990</year><volume>50</volume><fpage>5863</fpage><lpage>5867</lpage><pub-id pub-id-type="pmid">2393856</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buckley</surname><given-names>PG</given-names></name><name><surname>Mantripragada</surname><given-names>KK</given-names></name><name><surname>Benetkiewicz</surname><given-names>M</given-names></name><name><surname>Tapia-Paez</surname><given-names>I</given-names></name><name><surname>Diaz De Stahl</surname><given-names>T</given-names></name><name><surname>Rosenquist</surname><given-names>M</given-names></name><name><surname>Ali</surname><given-names>H</given-names></name><name><surname>Jarbo</surname><given-names>C</given-names></name><name><surname>De Bustos</surname><given-names>C</given-names></name><name><surname>Hirvela</surname><given-names>C</given-names></name><name><surname>Sinder Wilen</surname><given-names>B</given-names></name><name><surname>Fransson</surname><given-names>I</given-names></name><name><surname>Thyr</surname><given-names>C</given-names></name><name><surname>Johnsson</surname><given-names>BI</given-names></name><name><surname>Bruder</surname><given-names>CE</given-names></name><name><surname>Menzel</surname><given-names>U</given-names></name><name><surname>Hergersberg</surname><given-names>M</given-names></name><name><surname>Mandahl</surname><given-names>N</given-names></name><name><surname>Blennow</surname><given-names>E</given-names></name><name><surname>Wedell</surname><given-names>A</given-names></name><name><surname>Beare</surname><given-names>DM</given-names></name><name><surname>Collins</surname><given-names>JE</given-names></name><name><surname>Dunham</surname><given-names>I</given-names></name><name><surname>Albertson</surname><given-names>D</given-names></name><name><surname>Pinkel</surname><given-names>D</given-names></name><name><surname>Bastian</surname><given-names>BC</given-names></name><name><surname>Faruqi</surname><given-names>AF</given-names></name><name><surname>Lasken</surname><given-names>RS</given-names></name><name><surname>Ichimura</surname><given-names>K</given-names></name><name><surname>Collins</surname><given-names>VP</given-names></name><name><surname>Dumanski</surname><given-names>JP</given-names></name></person-group><article-title>A full-coverage, high-resolution human chromosome 22 genomic microarray for clinical and research applications</article-title><source>Hum Mol Genet</source><year>2002</year><volume>11</volume><fpage>3221</fpage><lpage>3229</lpage><pub-id pub-id-type="pmid">12444106</pub-id><pub-id pub-id-type="doi">10.1093/hmg/11.25.3221</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peyrard</surname><given-names>M</given-names></name><name><surname>Fransson</surname><given-names>I</given-names></name><name><surname>Xie</surname><given-names>YG</given-names></name><name><surname>Han</surname><given-names>FY</given-names></name><name><surname>Ruttledge</surname><given-names>MH</given-names></name><name><surname>Swahn</surname><given-names>S</given-names></name><name><surname>Collins</surname><given-names>JE</given-names></name><name><surname>Dunham</surname><given-names>I</given-names></name><name><surname>Collins</surname><given-names>VP</given-names></name><name><surname>Dumanski</surname><given-names>JPP</given-names></name></person-group><article-title>Characterization of a new member of the human beta-adaptin gene family from chromosome 22q12, a candidate meningioma gene</article-title><source>Hum Mol Genet</source><year>1994</year><volume>3</volume><fpage>1393</fpage><lpage>1399</lpage><pub-id pub-id-type="pmid">7987321</pub-id><pub-id pub-id-type="doi">10.1093/hmg/3.8.1393</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruttledge</surname><given-names>MH</given-names></name><name><surname>Xie</surname><given-names>YG</given-names></name><name><surname>Han</surname><given-names>FY</given-names></name><name><surname>Peyrard</surname><given-names>M</given-names></name><name><surname>Collins</surname><given-names>VP</given-names></name><name><surname>Nordenskjold</surname><given-names>M</given-names></name><name><surname>Dumanski</surname><given-names>JP</given-names></name></person-group><article-title>Deletions on chromosome 22 in sporadic meningioma</article-title><source>Genes Chromosomes Cancer</source><year>1994</year><volume>10</volume><fpage>122</fpage><lpage>130</lpage><pub-id pub-id-type="pmid">7520265</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maru</surname><given-names>Y</given-names></name><name><surname>Witte</surname><given-names>ON</given-names></name></person-group><article-title>The BCR gene encodes a novel serine/threonine kinase activity within a single exon</article-title><source>Cell</source><year>1991</year><volume>67</volume><fpage>459</fpage><lpage>468</lpage><pub-id pub-id-type="pmid">1657398</pub-id><pub-id pub-id-type="doi">10.1016/0092-8674(91)90521-Y</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>D'Adamo</surname><given-names>DR</given-names></name><name><surname>Novick</surname><given-names>S</given-names></name><name><surname>Kahn</surname><given-names>JM</given-names></name><name><surname>Leonardi</surname><given-names>P</given-names></name><name><surname>Pellicer</surname><given-names>A</given-names></name></person-group><article-title>rsc: a novel oncogene with structural and functional homology with the gene family of exchange factors for Ral</article-title><source>Oncogene</source><year>1997</year><volume>14</volume><fpage>1295</fpage><lpage>1305</lpage><pub-id pub-id-type="pmid">9178890</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1200950</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leonardi</surname><given-names>P</given-names></name><name><surname>Kassin</surname><given-names>E</given-names></name><name><surname>Hernandez-Munoz</surname><given-names>I</given-names></name><name><surname>Diaz</surname><given-names>R</given-names></name><name><surname>Inghirami</surname><given-names>G</given-names></name><name><surname>Pellicer</surname><given-names>A</given-names></name></person-group><article-title>Human rgr: transforming activity and alteration in T-cell malignancies</article-title><source>Oncogene</source><year>2002</year><volume>21</volume><fpage>5108</fpage><lpage>5116</lpage><pub-id pub-id-type="pmid">12140761</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1205694</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>A</given-names></name><name><surname>Cai</surname><given-names>DX</given-names></name><name><surname>Scheithauer</surname><given-names>BW</given-names></name><name><surname>Swanson</surname><given-names>PE</given-names></name><name><surname>Lohse</surname><given-names>CM</given-names></name><name><surname>Newsham</surname><given-names>IF</given-names></name><name><surname>Weaver</surname><given-names>A</given-names></name><name><surname>Gutmann</surname><given-names>DH</given-names></name></person-group><article-title>Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases</article-title><source>J Neuropathol Exp Neurol</source><year>2000</year><volume>59</volume><fpage>872</fpage><lpage>879</lpage><pub-id pub-id-type="pmid">11079777</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jacoby</surname><given-names>LB</given-names></name><name><surname>MacCollin</surname><given-names>M</given-names></name><name><surname>Barone</surname><given-names>R</given-names></name><name><surname>Ramesh</surname><given-names>V</given-names></name><name><surname>Gusella</surname><given-names>JF</given-names></name></person-group><article-title>Frequency and distribution of NF2 mutations in schwannomas</article-title><source>Genes, Chromosomes &#x00026; Cancer</source><year>1996</year><volume>17</volume><fpage>45</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">8889506</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1098-2264(199609)17:1&#x0003c;45::AID-GCC7&#x0003e;3.0.CO;2-2</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Merel</surname><given-names>P</given-names></name><name><surname>Hoang-Xuan</surname><given-names>K</given-names></name><name><surname>Sanson</surname><given-names>M</given-names></name><name><surname>Moreau-Aubry</surname><given-names>A</given-names></name><name><surname>Bijlsma</surname><given-names>EK</given-names></name><name><surname>Lazaro</surname><given-names>C</given-names></name><name><surname>Moisan</surname><given-names>JP</given-names></name><name><surname>Resche</surname><given-names>F</given-names></name><name><surname>Nishisho</surname><given-names>I</given-names></name><name><surname>Estivill</surname><given-names>X</given-names></name><name><surname>Delattre</surname><given-names>JY</given-names></name><name><surname>Poisson</surname><given-names>M</given-names></name><name><surname>Theillet</surname><given-names>C</given-names></name><name><surname>Hulsebos</surname><given-names>T</given-names></name><name><surname>Delattre</surname><given-names>O</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name></person-group><article-title>Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas</article-title><source>Genes Chromosomes Cancer</source><year>1995</year><volume>13</volume><fpage>211</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">7669741</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Twist</surname><given-names>EC</given-names></name><name><surname>Ruttledge</surname><given-names>MH</given-names></name><name><surname>Rousseau</surname><given-names>M</given-names></name><name><surname>Sanson</surname><given-names>M</given-names></name><name><surname>Papi</surname><given-names>L</given-names></name><name><surname>Merel</surname><given-names>P</given-names></name><name><surname>Delattre</surname><given-names>O</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Rouleau</surname><given-names>GA</given-names></name></person-group><article-title>The neurofibromatosis type 2 gene is inactivated in schwannomas</article-title><source>Hum Mol Genet</source><year>1994</year><volume>3</volume><fpage>147</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">8162016</pub-id><pub-id pub-id-type="doi">10.1093/hmg/3.1.147</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Vitis</surname><given-names>LR</given-names></name><name><surname>Tedde</surname><given-names>A</given-names></name><name><surname>Vitelli</surname><given-names>F</given-names></name><name><surname>Ammannati</surname><given-names>F</given-names></name><name><surname>Mennonna</surname><given-names>P</given-names></name><name><surname>Bono</surname><given-names>P</given-names></name><name><surname>Grammatico</surname><given-names>B</given-names></name><name><surname>Grammatico</surname><given-names>P</given-names></name><name><surname>Radice</surname><given-names>P</given-names></name><name><surname>Bigozzi</surname><given-names>U</given-names></name><name><surname>Montali</surname><given-names>E</given-names></name><name><surname>Papi</surname><given-names>L</given-names></name></person-group><article-title>Analysis of the neurofibromatosis type 2 gene in different human tumors of neuroectodermal origin</article-title><source>Hum Genet</source><year>1996</year><volume>97</volume><fpage>638</fpage><lpage>641</lpage><pub-id pub-id-type="pmid">8655145</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>HM</given-names></name><name><surname>Gutmann</surname><given-names>DH</given-names></name></person-group><article-title>Merlin differentially associates with the microtubule and actin cytoskeleton</article-title><source>J Neurosci Res</source><year>1998</year><volume>51</volume><fpage>403</fpage><lpage>415</lpage><pub-id pub-id-type="pmid">9486775</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1097-4547(19980201)51:3&#x0003c;403::AID-JNR13&#x0003e;3.0.CO;2-7</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gutmann</surname><given-names>DH</given-names></name><name><surname>Haipek</surname><given-names>CA</given-names></name><name><surname>Hoang Lu</surname><given-names>K</given-names></name></person-group><article-title>Neurofibromatosis 2 tumor suppressor protein, merlin, forms two functionally important intramolecular associations</article-title><source>J Neurosci Res</source><year>1999</year><volume>58</volume><fpage>706</fpage><lpage>716</lpage><pub-id pub-id-type="pmid">10561699</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1097-4547(19991201)58:5&#x0003c;706::AID-JNR12&#x0003e;3.0.CO;2-Z</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kino</surname><given-names>T</given-names></name><name><surname>Takeshima</surname><given-names>H</given-names></name><name><surname>Nakao</surname><given-names>M</given-names></name><name><surname>Nishi</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Kochi</surname><given-names>M</given-names></name><name><surname>Kuratsu</surname><given-names>J</given-names></name><name><surname>Saya</surname><given-names>H</given-names></name><name><surname>Ushio</surname><given-names>Y</given-names></name></person-group><article-title>Identification of the cis-acting region in the NF2 gene promoter as a potential target for mutation and methylation-dependent silencing in schwannoma</article-title><source>Genes Cells</source><year>2001</year><volume>6</volume><fpage>441</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">11380622</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2443.2001.00432.x</pub-id></citation></ref><ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bello</surname><given-names>MJ</given-names></name><name><surname>Aminoso</surname><given-names>C</given-names></name><name><surname>Lopez-Marin</surname><given-names>I</given-names></name><name><surname>Arjona</surname><given-names>D</given-names></name><name><surname>Gonzalez-Gomez</surname><given-names>P</given-names></name><name><surname>Alonso</surname><given-names>ME</given-names></name><name><surname>Lomas</surname><given-names>J</given-names></name><name><surname>de Campos</surname><given-names>JM</given-names></name><name><surname>Kusak</surname><given-names>ME</given-names></name><name><surname>Vaquero</surname><given-names>J</given-names></name><name><surname>Isla</surname><given-names>A</given-names></name><name><surname>Gutierrez</surname><given-names>M</given-names></name><name><surname>Sarasa</surname><given-names>JL</given-names></name><name><surname>Rey</surname><given-names>JA</given-names></name></person-group><article-title>DNA methylation of multiple promoter-associated CpG islands in meningiomas: relationship with the allelic status at 1p and 22q</article-title><source>Acta Neuropathol (Berl)</source><year>2004</year><volume>108</volume><fpage>413</fpage><lpage>421</lpage><pub-id pub-id-type="pmid">15365725</pub-id><pub-id pub-id-type="doi">10.1007/s00401-004-0911-6</pub-id></citation></ref><ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Pang</surname><given-names>JC</given-names></name><name><surname>Dong</surname><given-names>S</given-names></name><name><surname>Mao</surname><given-names>B</given-names></name><name><surname>Poon</surname><given-names>WS</given-names></name><name><surname>Ng</surname><given-names>HK</given-names></name></person-group><article-title>Aberrant CpG island hypermethylation profile is associated with atypical and anaplastic meningiomas</article-title><source>Hum Pathol</source><year>2005</year><volume>36</volume><fpage>416</fpage><lpage>425</lpage><pub-id pub-id-type="pmid">15892004</pub-id><pub-id pub-id-type="doi">10.1016/j.humpath.2005.02.006</pub-id></citation></ref><ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Colella</surname><given-names>S</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Baggerly</surname><given-names>KA</given-names></name><name><surname>Issa</surname><given-names>JP</given-names></name><name><surname>Krahe</surname><given-names>R</given-names></name></person-group><article-title>Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites</article-title><source>Biotechniques</source><year>2003</year><volume>35</volume><fpage>146</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">12866414</pub-id></citation></ref><ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uhlmann</surname><given-names>K</given-names></name><name><surname>Brinckmann</surname><given-names>A</given-names></name><name><surname>Toliat</surname><given-names>MR</given-names></name><name><surname>Ritter</surname><given-names>H</given-names></name><name><surname>Nurnberg</surname><given-names>P</given-names></name></person-group><article-title>Evaluation of a potential epigenetic biomarker by quantitative methyl-single nucleotide polymorphism analysis</article-title><source>Electrophoresis</source><year>2002</year><volume>23</volume><fpage>4072</fpage><lpage>4079</lpage><pub-id pub-id-type="pmid">12481262</pub-id><pub-id pub-id-type="doi">10.1002/elps.200290023</pub-id></citation></ref><ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Sundaram</surname><given-names>V</given-names></name><name><surname>Stein</surname><given-names>DJ</given-names></name><name><surname>Kinney</surname><given-names>SE</given-names></name><name><surname>Stacey</surname><given-names>DW</given-names></name><name><surname>Golubic</surname><given-names>M</given-names></name></person-group><article-title>Reduced expression of schwannomin/merlin in human sporadic meningiomas</article-title><source>Neurosurgery</source><year>1997</year><volume>40</volume><fpage>578</fpage><lpage>587</lpage><pub-id pub-id-type="pmid">9055299</pub-id><pub-id pub-id-type="doi">10.1097/00006123-199703000-00031</pub-id></citation></ref><ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hitotsumatsu</surname><given-names>T</given-names></name><name><surname>Iwaki</surname><given-names>T</given-names></name><name><surname>Kitamoto</surname><given-names>T</given-names></name><name><surname>Mizoguchi</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>SO</given-names></name><name><surname>Hamada</surname><given-names>Y</given-names></name><name><surname>Fukui</surname><given-names>M</given-names></name><name><surname>Tateishi</surname><given-names>J</given-names></name></person-group><article-title>Expression of neurofibromatosis 2 protein in human brain tumors: an immunohistochemical study</article-title><source>Acta Neuropathol (Berl)</source><year>1997</year><volume>93</volume><fpage>225</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">9083553</pub-id><pub-id pub-id-type="doi">10.1007/s004010050608</pub-id></citation></ref><ref id="B57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Den Bakker</surname><given-names>MA</given-names></name><name><surname>van Tilborg</surname><given-names>AA</given-names></name><name><surname>Kros</surname><given-names>JM</given-names></name><name><surname>Zwarthoff</surname><given-names>EC</given-names></name></person-group><article-title>Truncated NF2 proteins are not detected in meningiomas and schwannomas</article-title><source>Neuropathology</source><year>2001</year><volume>21</volume><fpage>168</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">11666013</pub-id><pub-id pub-id-type="doi">10.1046/j.1440-1789.2001.00394.x</pub-id></citation></ref><ref id="B58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hernandez-Munoz</surname><given-names>I</given-names></name><name><surname>Benet</surname><given-names>M</given-names></name><name><surname>Calero</surname><given-names>M</given-names></name><name><surname>Jimenez</surname><given-names>M</given-names></name><name><surname>Diaz</surname><given-names>R</given-names></name><name><surname>Pellicer</surname><given-names>A</given-names></name></person-group><article-title>rgr oncogene: activation by elimination of translational controls and mislocalization</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>4188</fpage><lpage>4195</lpage><pub-id pub-id-type="pmid">12874025</pub-id></citation></ref><ref id="B59"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Sambrook</surname><given-names>J</given-names></name><name><surname>Fritsch</surname><given-names>EF</given-names></name><name><surname>Maniatis</surname><given-names>T</given-names></name></person-group><source>Molecular cloning; a laboratory manual</source><year>1989</year><edition>Second Edition</edition><publisher-name>Cold Spring Harbor, New York , Cold Spring Harbor Laboratory Press</publisher-name></citation></ref><ref id="B60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fiegler</surname><given-names>H</given-names></name><name><surname>Carr</surname><given-names>P</given-names></name><name><surname>Douglas</surname><given-names>EJ</given-names></name><name><surname>Burford</surname><given-names>DC</given-names></name><name><surname>Hunt</surname><given-names>S</given-names></name><name><surname>Scott</surname><given-names>CE</given-names></name><name><surname>Smith</surname><given-names>J</given-names></name><name><surname>Vetrie</surname><given-names>D</given-names></name><name><surname>Gorman</surname><given-names>P</given-names></name><name><surname>Tomlinson</surname><given-names>IP</given-names></name><name><surname>Carter</surname><given-names>NP</given-names></name></person-group><article-title>DNA microarrays for comparative genomic hybridization based on DOP-PCR amplification of BAC and PAC clones</article-title><source>Genes Chromosomes Cancer</source><year>2003</year><volume>36</volume><fpage>361</fpage><lpage>374</lpage><pub-id pub-id-type="pmid">12619160</pub-id><pub-id pub-id-type="doi">10.1002/gcc.10155</pub-id></citation></ref><ref id="B61"><citation citation-type="other"><person-group person-group-type="author"><collab>http://puffer.genpat.uu.se/protocols</collab></person-group></citation></ref><ref id="B62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Staden</surname><given-names>R</given-names></name></person-group><article-title>The Staden sequence analysis package</article-title><source>Mol Biotechnol</source><year>1996</year><volume>5</volume><fpage>233</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">8837029</pub-id></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Summary of array-CGH profiles for chromosome 22 insporadic meningioma</bold>. <bold>A) </bold>Detailed summary of all complex aberrations. Deletions and gains are mapped according to the clones present on the chromosome 22 minimal tiling path array. Chromosome 22 clones are grouped in bins of 10 along the y-axis. The panel of tumors which displayed complex aberrations of chromosome 22 is shown from left to right. The red, yellow and blue boxes denote hemizygous deletion, biallelic deletion and gain, respectively. The horizontal dashed line displays the approximate position of the <italic>NF2 </italic>gene in relation to the measurement points on the chromosome 22 minimal tiling path array. The table below details the clone ID's at which the deletion/gain starts and finishes. Smallest regions of overlapping deletions are highlighted with grey lines (R1 and R2) and genes present within these regions are shown to the left. Tumor names highlighted in bold are displayed in more detail in other figures. <bold>B) </bold>Detailed view of candidate region 1 (R1) with gene and clone information presented according to the positions on chromosome 22 sequence (UCSC Homo sapiens Genome Browser, assembly July 2003). <bold>C) </bold>Detailed view of candidate region 2 (R2) with gene and clone information presented according to the positions on chromosome 22 sequence (UCSC Homo sapiens Genome Browser, assembly July 2003).</p></caption><graphic xlink:href="1471-2164-8-16-1"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Array-CGH profiles of chromosome 22 in tumors displaying complex aberrations</bold>. The chromosome 22 array-CGH plots consist of 480 chromosome 22 clones ordered from centromere to telomere and 9 chromosome X controls between the vertical lines, as well as 31 non-chromosome 22 controls plotted on the right hand side. The y-axis displays the raw fluorescent intensity ratios for each clone on the genomic array. The position of the <italic>NF2 </italic>gene is highlighted with the vertical grey bar. <bold>A) </bold>Array-CGH profile of case M64 displaying a single copy loss of the majority of the chromosome with a biallelic deletion encompassing a single measurement point (clone ID 151) [GenBank:<ext-link ext-link-type="gen" xlink:href="AC005529">AC005529</ext-link>], specifically targeting the <italic>NF2 </italic>gene (highlighted by a grey circle). Encircled clones centromeric of <italic>NF2 </italic>display fluorescent ratio consistent with two copies; clone IDs 61&#x02013;63 [GenBank:<ext-link ext-link-type="gen" xlink:href="D87000">D87000</ext-link>&#x02013;<ext-link ext-link-type="gen" xlink:href="D87003">D87003</ext-link>] (previously reported Copy Number Polymorphism, CNP) and clone IDs 99&#x02013;100 [GenBank:<ext-link ext-link-type="gen" xlink:href="AL049759">AL049759</ext-link>&#x02013;<ext-link ext-link-type="gen" xlink:href="AL050312">AL050312</ext-link>]. Clone ID 400 [GenBank:<ext-link ext-link-type="gen" xlink:href="Z84478">Z84478</ext-link>] positioned towards the telomere, also exhibit two gene copies (highlighted by a circle). Control clone derived from chromosome 10 encompassing <italic>SUFU1B </italic>gene presents with one copy loss (highlighted by a circle). <bold>B) </bold>Array-CGH profile of case M32 displaying an interstitial deletion encompassing the <italic>NF2 </italic>gene and a terminal deletion. Clones spanning the <italic>DAL-1 </italic>gene on chromosome 18 and clones spanning the <italic>PTCH1B </italic>locus on chromosome 9 display a fluorescent ratio consistent with a one copy loss are highlighted by a circle. <bold>C) </bold>Case M109 displaying a gain spanning clone IDs 5&#x02013;48 [Genbank:<ext-link ext-link-type="gen" xlink:href="AC006548">AC006548</ext-link>&#x02013;<ext-link ext-link-type="gen" xlink:href="AC007957">AC007957</ext-link>] followed by a large terminal deletion covering clones 49&#x02013;480 [Genbank:<ext-link ext-link-type="gen" xlink:href="AC009516">AC009516</ext-link>&#x02013;<ext-link ext-link-type="gen" xlink:href="AC002055">AC002055</ext-link>]. Two CNPs are positioned at clone IDs 13&#x02013;15 and 63 [Genbank: <ext-link ext-link-type="gen" xlink:href="AC008079">AC008079</ext-link>&#x02013;<ext-link ext-link-type="gen" xlink:href="AC008132">AC008132</ext-link> and <ext-link ext-link-type="gen" xlink:href="D87003">D87003</ext-link>] and are indicated by circles. <bold>D) </bold>Meningioma M101 displaying a large one copy loss for the majority of the chromosome apart from a region encompassing clone IDs 348&#x02013;366 [GenBank:<ext-link ext-link-type="gen" xlink:href="AL080242">AL080242</ext-link>&#x02013;<ext-link ext-link-type="gen" xlink:href="Z82176">Z82176</ext-link>] and a CNP spanning clone IDs 60&#x02013;61 [GenBank:<ext-link ext-link-type="gen" xlink:href="D88269">D88269</ext-link>&#x02013;<ext-link ext-link-type="gen" xlink:href="D87000">D87000</ext-link>]. <bold>E) </bold>Detection of multiple interstitial deletions outside the <italic>NF2 </italic>region, spanning clone IDs 85&#x02013;89 (R1, highlighted by a circle), 181&#x02013;262 and 311&#x02013;360 [GenBank: <ext-link ext-link-type="gen" xlink:href="U07000">U07000</ext-link>&#x02013;<ext-link ext-link-type="gen" xlink:href="AP000348">AP000348</ext-link>, <ext-link ext-link-type="gen" xlink:href="AC005004">AC005004</ext-link>&#x02013;<ext-link ext-link-type="gen" xlink:href="Z69907">Z69907</ext-link> and <ext-link ext-link-type="gen" xlink:href="AL022311">AL022311</ext-link>&#x02013;<ext-link ext-link-type="gen" xlink:href="Z83851">Z83851</ext-link>] and a terminal deletion covering clone IDs 390&#x02013;480 [GenBank:<ext-link ext-link-type="gen" xlink:href="Z93244">Z93244</ext-link>&#x02013;<ext-link ext-link-type="gen" xlink:href="AC002055">AC002055</ext-link>] in case M11. A CNP spanning clone IDs 14&#x02013;15 [GenBank:<ext-link ext-link-type="gen" xlink:href="AC008132">AC008132</ext-link>&#x02013;<ext-link ext-link-type="gen" xlink:href="AC008103">AC008103</ext-link>] is highlighted by a circle.</p></caption><graphic xlink:href="1471-2164-8-16-2"/></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>Detection of cellular or genetic heterogeneity in meningioma samples</bold>. The array-CGH plots follow the same general scheme as for Figure 3. However, the data points are shaded in grey and a trend line (with a moving average of 10 data points) is shown, which highlights the difference in fluorescent ratio levels along the chromosome. <bold>A</bold>) Identification of genetic heterogeneity in meningioma sample M96 which displays 3 different fluorescent ratio values across chromosome 22. The clone IDs and <bold>A</bold>verage <bold>N</bold>ormalized <bold>I</bold>nter <bold>L</bold>ocus <bold>F</bold>luorescence <bold>R</bold>atio (ANILFR) for each of these are 1&#x02013;15, 0.95; 16&#x02013;84, 1.1 and 85&#x02013;480, 0.83, respectively. <bold>B</bold>) Array-CGH profile of a complex set of aberrations on chromosome 22, which suggest genetic/cellular heterogeneity within the tumor M90. The regional shifts in fluorescent ratio across chromosome 22 are as summarized with the clone IDs and their ANILFR value; 1&#x02013;23, 0.95; 24&#x02013;66, 0.90; 67&#x02013;214, 0.76; 215&#x02013;284, 0.88; 285&#x02013;303, 1.09; 304&#x02013;326, 0.87; 327&#x02013;480, 0.76. The non-chromosome 22 autosomal controls have an ANILFR value of 1.00, since this value was used to normalize all values across the genomic array.</p></caption><graphic xlink:href="1471-2164-8-16-3"/></fig><fig position="float" id="F4"><label>Figure 4</label><caption><p><bold>Overview of the <italic>NF2 </italic>locus analyzed for point mutations and methylation of CpG dinucleotides</bold>. <bold>A) </bold>Illustration of the <italic>NF2 </italic>gene displaying exons (black boxes) and conserved non-genic sequences (CNGs) (green boxes) that were analyzed for point mutations. Gene orientation is displayed with an arrow next to the gene name. The scale is according to sequence position on chromosome 22 in million base pairs (Mb) (UCSC Homo sapiens Genome Browser, assembly July 2003). <bold>B) </bold>Schematic view of the CpG sites in the 5' part of the <italic>NF2 </italic>gene that were analyzed for methylation. The 40 sequenced CpG sites were located between positions -591 and +166 bp (position +1 refers to transcriptional start site). A single methylated CpG site was detected in tumor M104 at position +120 in ~40% of DNA molecules (displayed as a red filled circle).</p></caption><graphic xlink:href="1471-2164-8-16-4"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Genetic alterations in one hundred meningiomas.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">Sample ID</td><td align="center">Subtype<sup>1</sup></td><td align="center">CH<sub>3</sub></td><td align="center" colspan="3"><underline>NF2 gene mutations</underline></td><td align="center" colspan="2"><underline>DNA copy number profiles<sup>4</sup></underline></td><td></td></tr><tr><td></td><td></td><td></td><td align="left">Position</td><td align="center">Mutation<sup>2</sup></td><td align="center">Assumed effect<sup>3</sup></td><td align="center">Chromosome 22</td><td align="center">Chromosome 1</td><td align="left">Loss of non-22 genes<sup>5</sup></td></tr></thead><tbody><tr><td align="left">M26</td><td align="left">A</td><td></td><td align="left">Ex 2</td><td align="left">227_240del</td><td align="left">Lys76fs</td><td align="left">Monosomy</td><td align="left">Monosomy</td><td align="left">D1, S1A, S1B</td></tr><tr><td align="left">M71</td><td align="left">A</td><td></td><td align="left">Ex8</td><td align="left">810+2T&#x0003e;C</td><td align="left">Abn. Spl.</td><td align="left">Monosomy</td><td align="left">1p, 120.8 Mb TD</td><td align="left">D1, P2A, S1A, S1B</td></tr><tr><td align="left">M38</td><td align="left">A</td><td></td><td align="left">Ex6</td><td align="left">573del; 575_581del</td><td align="left">Trp191fs</td><td align="left">Monosomy</td><td align="left">1p 107.9 Mb TD</td><td align="left">P1B, P2A, S1A, S1B</td></tr><tr><td align="left">M43</td><td align="left">A</td><td></td><td align="left">Ex12</td><td align="left">1185del</td><td align="left">Lys396fs</td><td align="left">Monosomy</td><td align="left">1p 120.3 Mb TD, 4.4 Mb A</td><td></td></tr><tr><td align="left">M46</td><td align="left">A</td><td></td><td align="left">Ex8</td><td align="left">810+2T&#x0003e;C</td><td align="left">Abn. Spl.</td><td align="left">NAD</td><td align="left">NAD</td><td></td></tr><tr><td align="left">M33</td><td align="left">A</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">30.6 Mb TD [AC009516-AC002055]</td><td align="left">1p, 90.2 Mb TD, 45.8 Mb ID</td><td></td></tr><tr><td align="left">M9</td><td align="left">A</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NAD</td><td></td></tr><tr><td align="left">M20</td><td align="left">A</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NAD</td><td></td></tr><tr><td align="left">M13</td><td align="left">F</td><td></td><td align="left">Ex 2</td><td align="left">240+2T&#x0003e;C</td><td align="left">Abn. Spl.</td><td align="left">Monosomy</td><td align="left">1p, 142.9 Mb TD</td><td align="left">P2A, S1A, S1B</td></tr><tr><td align="left">M88</td><td align="left">F</td><td></td><td align="left">Ex4</td><td align="left">364-1G&#x0003e;A</td><td align="left">Abn. Spl.</td><td align="left">Monosomy</td><td align="left">1p 84.1 Mb TD; 1q 4.6, 7.1 Mb IDs, 12.5 Mb TD</td><td align="left">P2A</td></tr><tr><td align="left">M3</td><td align="left">F</td><td></td><td align="left">Ex 2</td><td align="left">240+2T&#x0003e;C</td><td align="left">Abn. Spl.</td><td align="left">Monosomy</td><td align="left">1p 119.8 Mb TD</td><td></td></tr><tr><td align="left">M14</td><td align="left">F</td><td></td><td align="left">Ex3</td><td align="left">249del</td><td align="left">His84fs</td><td align="left">Monosomy</td><td align="left">1p 120.2 Mb TD</td><td></td></tr><tr><td align="left">M15</td><td align="left">F</td><td></td><td align="left">Ex8</td><td align="left">683del</td><td align="left">Lys228fs</td><td align="left">Monosomy</td><td align="left">1p 116.0 Mb TD</td><td></td></tr><tr><td align="left">M39</td><td align="left">F</td><td></td><td align="left">Ex8</td><td align="left">810+1G&#x0003e;A</td><td align="left">Abn. Spl.</td><td align="left">Monosomy</td><td align="left">NS</td><td></td></tr><tr><td align="left">M42</td><td align="left">F</td><td></td><td align="left">Ex10</td><td align="left">995del</td><td align="left">Lys332fs</td><td align="left">Monosomy</td><td align="left">NS</td><td></td></tr><tr><td align="left">M70</td><td align="left">F</td><td></td><td align="left">Ex6</td><td align="left">599+1G&#x0003e;A</td><td align="left">Abn. Spl.</td><td align="left">Monosomy</td><td align="left">NS</td><td></td></tr><tr><td align="left">M91</td><td align="left">F</td><td></td><td align="left">Ex 2</td><td align="left">154del</td><td align="left">Arg52fs</td><td align="left">Monosomy</td><td align="left">NS</td><td></td></tr><tr><td align="left">M102</td><td align="left">F</td><td></td><td align="left">Ex9</td><td align="left">865A&#x0003e;T</td><td align="left">Lys289X</td><td align="left">Monosomy</td><td align="left">NS</td><td></td></tr><tr><td align="left">M115</td><td align="left">F</td><td></td><td align="left">Ex7</td><td align="left">634C&#x0003e;T</td><td align="left">Gln212X</td><td align="left">NAD</td><td align="left">1p 119.6 Mb TD</td><td></td></tr><tr><td align="left">M64<sup>6</sup></td><td align="left">F</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">30.4 Mb TD [AC008079-AC002055], <italic>NF2 </italic>biallelic del [AC005529]</td><td align="left">1p 98.8 Mb ID; 1q 24.2 Mb ID</td><td align="left">P1B, P2A</td></tr><tr><td align="left">M66</td><td align="left">F</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">Monosomy</td><td align="left">1p 118.1 Mb TD</td><td align="left">P2A</td></tr><tr><td align="left">M11<sup>7</sup></td><td align="left">F</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">0.55, 2.8, 4.5 Mb IDs [U07000-AP00034, AC005004-Z69907, AL022311-Z83851]; 5.9 Mb TD [Z93244-AC002055]</td><td align="left">1p 116.8 Mb TD, 3.6 Mb A</td><td></td></tr><tr><td align="left">M32</td><td align="left">F</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">5.3 Mb ID [AL022329-AL022336], 15.2 Mb TD [AL009049-AC002055]</td><td align="left">NS</td><td align="left">D1</td></tr><tr><td align="left">M4</td><td align="left">F</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">Monosomy</td><td align="left">NAD</td><td></td></tr><tr><td align="left">M29</td><td align="left">F</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">Monosomy</td><td align="left">NS</td><td></td></tr><tr><td align="left">M41</td><td align="left">F</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">Monosomy</td><td align="left">NS</td><td></td></tr><tr><td align="left">M92</td><td align="left">F</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">Monosomy</td><td align="left">NS</td><td></td></tr><tr><td align="left">M114</td><td align="left">F</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">18.0 Mb ID [AP000525-Z68324]</td><td align="left">NS</td><td></td></tr><tr><td align="left">M119</td><td align="left">F</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NS</td><td></td></tr><tr><td align="left">M10</td><td align="left">M</td><td></td><td align="left">Ex13</td><td align="left">1341-2A&#x0003e;G</td><td align="left">Abn. Spl.</td><td align="left">Monosomy</td><td align="left">1p 120.3 Mb TD</td><td align="left">P2A</td></tr><tr><td align="left">M23</td><td align="left">M</td><td></td><td align="left">Ex3</td><td align="left">241-2A&#x0003e;C</td><td align="left">Abn. Spl.</td><td align="left">Monosomy</td><td align="left">1p 120.9 Mb TD</td><td align="left">P2A</td></tr><tr><td align="left">M67</td><td align="left">M</td><td></td><td align="left">Ex4</td><td align="left">432C&#x0003e;A</td><td align="left">Tyr144X</td><td align="left">Monosomy</td><td align="left">1p 120.8 Mb TD</td><td align="left">P2A</td></tr><tr><td align="left">M98</td><td align="left">M</td><td></td><td align="left">Ex14</td><td align="left">1519_1520del</td><td align="left">Phe507fs</td><td align="left">Monosomy</td><td align="left">NAD</td><td align="left">D1, P2A, S1A, S1B</td></tr><tr><td align="left">M57</td><td align="left">M</td><td></td><td align="left">Ex 2</td><td align="left">133_144 del</td><td align="left">Asp45fs</td><td align="left">Monosomy</td><td align="left">NS</td><td></td></tr><tr><td align="left">M72</td><td align="left">M</td><td></td><td align="left">Ex7</td><td align="left">634C&#x0003e;T</td><td align="left">Gln212X</td><td align="left">Monosomy</td><td align="left">NS</td><td></td></tr><tr><td align="left">M40</td><td align="left">M</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">Monosomy</td><td align="left">1p 164.9 Mb TD</td><td align="left">P1B, P2A</td></tr><tr><td align="left">M76</td><td align="left">M</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">Monosomy</td><td align="left">1p 142.7 Mb TD</td><td align="left">P2A</td></tr><tr><td align="left">M105</td><td align="left">M</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">Monosomy</td><td align="left">1p 116.3 Mb TD</td><td align="left">P1B, P2A</td></tr><tr><td align="left">M34<sup>8</sup></td><td align="left">M</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">20.0 Mb TD [AC004542-AC002055]</td><td align="left">1p 102.8 Mb ID</td><td></td></tr><tr><td align="left">M44</td><td align="left">M</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">Monosomy</td><td align="left">1p 85.4 Mb TD</td><td></td></tr><tr><td align="left">M101</td><td align="left">M</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">25.1 Mb ID [AP000525-AL035450], 7.9 Mb TD [AL049758-AC002055]</td><td align="left">Monosomy, 1p 2.1 Mb R</td><td></td></tr><tr><td align="left">M30</td><td align="left">M</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">Monosomy</td><td align="left">NAD</td><td align="left">D1, P2A</td></tr><tr><td align="left">M112</td><td align="left">M</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">1p 114.2 Mb TD</td><td></td></tr><tr><td align="left">M2</td><td align="left">M</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NAD</td><td></td></tr><tr><td align="left">M5</td><td align="left">M</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NAD</td><td></td></tr><tr><td align="left">M77</td><td align="left">M</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NAD</td><td></td></tr><tr><td align="left">M82</td><td align="left">M</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NAD</td><td></td></tr><tr><td align="left">M45</td><td align="left">M</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NS</td><td></td></tr><tr><td align="left">M51</td><td align="left">M</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NS</td><td></td></tr><tr><td align="left">M54</td><td align="left">M</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NS</td><td></td></tr><tr><td align="left">M61</td><td align="left">M</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NS</td><td></td></tr><tr><td align="left">M63</td><td align="left">M</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NS</td><td></td></tr><tr><td align="left">M65</td><td align="left">M</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NS</td><td></td></tr><tr><td align="left">M69</td><td align="left">M</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NS</td><td></td></tr><tr><td align="left">M86</td><td align="left">M</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NS</td><td></td></tr><tr><td align="left">M95</td><td align="left">M</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NS</td><td></td></tr><tr><td align="left">M99</td><td align="left">M</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NS</td><td></td></tr><tr><td align="left">M107</td><td align="left">M</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NS</td><td></td></tr><tr><td align="left">M108</td><td align="left">M</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NS</td><td></td></tr><tr><td align="left">M111</td><td align="left">M</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NS</td><td></td></tr><tr><td align="left">M116</td><td align="left">M</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NS</td><td></td></tr><tr><td align="left">M120</td><td align="left">M</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NS</td><td></td></tr><tr><td align="left">M93</td><td align="left">P</td><td></td><td align="left">Ex8</td><td align="left">810G&#x0003e;T</td><td align="left">Glu270Asp</td><td align="left">Monosomy</td><td align="left">1p 114.3 Mb ID</td><td align="left">P2A</td></tr><tr><td align="left">M22<sup>9</sup></td><td align="left">P</td><td></td><td align="left">Ex13, inter1</td><td align="left">1390del; 28309611 C&#x0003e;A</td><td align="left">Ala464fs, unknown</td><td align="left">Monosomy</td><td align="left">NS</td><td></td></tr><tr><td align="left">M62</td><td align="left">P</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">Monosomy</td><td align="left">NS</td><td></td></tr><tr><td align="left">M21</td><td align="left">P</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NS</td><td></td></tr><tr><td align="left">M60</td><td align="left">T</td><td></td><td align="left">Ex14</td><td align="left">1519_1528del</td><td align="left">Phe507fs</td><td align="left">Monosomy</td><td align="left">1p 118.2 Mb TD</td><td align="left">P2A</td></tr><tr><td align="left">M1</td><td align="left">T</td><td></td><td align="left">Ex7</td><td align="left">650del</td><td align="left">Tyr217X</td><td align="left">Monosomy</td><td align="left">1p 65.0 Mb TD</td><td></td></tr><tr><td align="left">M31</td><td align="left">T</td><td></td><td align="left">Ex13</td><td align="left">1325del</td><td align="left">Ala451fs</td><td align="left">Monosomy</td><td align="left">1p 53.2, 36.3 Mb IDs</td><td></td></tr><tr><td align="left">M58</td><td align="left">T</td><td></td><td align="left">Ex 2</td><td align="left">115-3G&#x0003e;C</td><td align="left">Abn. Spl.</td><td align="left">30.1 Mb TD [AC007050-AC002055]</td><td align="left">1p 120.2 Mb TD</td><td></td></tr><tr><td align="left">M90</td><td align="left">T</td><td></td><td align="left">Ex3</td><td align="left">241-2A&#x0003e;G</td><td align="left">Abn. Spl.</td><td align="left">20.1Mb ID [AP000525-AL079295], 13.4 Mb TD [AL049850-AC002055]</td><td align="left">1p 83.3 Mb TD</td><td></td></tr><tr><td align="left">M96</td><td align="left">T</td><td></td><td align="left">Ex12</td><td align="left">1175G&#x0003e;T</td><td align="left">Glu392X</td><td align="left">2.0 Mb ID [AP000525-AC007666], 5.4 Mb A [AC006285-AC000102], 27.5 Mb TD [U07000-AC002055]</td><td align="left">1p 43.3 Mb TD, 1q 69.9 Mb TD</td><td></td></tr><tr><td align="left">M52</td><td align="left">T</td><td></td><td align="left">Ex4</td><td align="left">431_432insAA</td><td align="left">Tyr144X</td><td align="left">Monosomy</td><td align="left">NS</td><td align="left">P1B</td></tr><tr><td align="left">M113</td><td align="left">T</td><td></td><td align="left">Ex4</td><td align="left">377del</td><td align="left">Leu127X</td><td align="left">Monosomy</td><td align="left">NAD</td><td align="left">D1, P1B, P2A, S1A, S1B</td></tr><tr><td align="left">M18</td><td align="left">T</td><td></td><td align="left">Ex12</td><td align="left">1198C&#x0003e;T</td><td align="left">Gln400X</td><td align="left">Monosomy</td><td align="left">NS</td><td></td></tr><tr><td align="left">M37</td><td align="left">T</td><td></td><td align="left">Ex8</td><td align="left">745_755del</td><td align="left">Arg249fs</td><td align="left">Monosomy</td><td align="left">NS</td><td></td></tr><tr><td align="left">M48</td><td align="left">T</td><td></td><td align="left">Ex 1</td><td align="left">36_37del</td><td align="left">Leu14fs</td><td align="left">Monosomy</td><td align="left">NS</td><td></td></tr><tr><td align="left">M75</td><td align="left">T</td><td></td><td align="left">Ex8</td><td align="left">750del</td><td align="left">Thr251fs</td><td align="left">Monosomy</td><td align="left">NS</td><td></td></tr><tr><td align="left">M87</td><td align="left">T</td><td></td><td align="left">Ex4</td><td align="left">436G&#x0003e;A</td><td align="left">Val146Ile</td><td align="left">NAD</td><td align="left">NS</td><td></td></tr><tr><td align="left">M56</td><td align="left">T</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">Monosomy</td><td align="left">1p 116.5 Mb TD</td><td align="left">P2A</td></tr><tr><td align="left">M85</td><td align="left">T</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">Monosomy</td><td align="left">1p 108.2 Mb TD</td><td align="left">P2A</td></tr><tr><td align="left">M109</td><td align="left">T</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">5.7 Mb A [AC006548-AC007957], 30.6 Mb TD [AC009516-AC002055]</td><td align="left">1p 120.2 Mb TD</td><td></td></tr><tr><td align="left">M27</td><td align="left">T</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">15.5Mb ID [AP000525-AC005005], 14.1 Mb TD [AL049749-AC002055]</td><td align="left">NS</td><td></td></tr><tr><td align="left">M59</td><td align="left">T</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">Monosomy</td><td align="left">NS</td><td></td></tr><tr><td align="left">M68</td><td align="left">T</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">Monosomy</td><td align="left">NS</td><td></td></tr><tr><td align="left">M94</td><td align="left">T</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">Monosomy</td><td align="left">NS</td><td></td></tr><tr><td align="left">M97</td><td align="left">T</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">Monosomy</td><td align="left">NS</td><td></td></tr><tr><td align="left">M25</td><td align="left">T</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">1p 98.7 Mb TD</td><td></td></tr><tr><td align="left">M117</td><td align="left">T</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">1p 36.1 Mb TD</td><td></td></tr><tr><td align="left">M104<sup>10</sup></td><td align="left">T</td><td align="left">+</td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NS</td><td></td></tr><tr><td align="left">M8</td><td align="left">T</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NS</td><td></td></tr><tr><td align="left">M12</td><td align="left">T</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NS</td><td></td></tr><tr><td align="left">M17</td><td align="left">T</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NS</td><td></td></tr><tr><td align="left">M35</td><td align="left">T</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NS</td><td></td></tr><tr><td align="left">M55</td><td align="left">T</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NS</td><td></td></tr><tr><td align="left">M89</td><td align="left">T</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NS</td><td></td></tr><tr><td align="left">M103</td><td align="left">T</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NS</td><td></td></tr><tr><td align="left">M78</td><td align="left">U</td><td></td><td align="left">Ex10</td><td align="left">999+1G&#x0003e;T</td><td align="left">Abn. Spl.</td><td align="left">Monosomy</td><td align="left">1p 3.8 Mb TD</td><td></td></tr><tr><td align="left">M79</td><td align="left">U</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">1p 39.1Mb ID, 1q 41.3Mb TD</td><td></td></tr><tr><td align="left">M83</td><td align="left">U</td><td></td><td></td><td align="left">NAD</td><td></td><td align="left">NAD</td><td align="left">NS</td><td></td></tr></tbody></table><table-wrap-foot><p><bold>1 </bold>Tumors are grouped according to histopathological subtypes. Abbreviations: A, Anaplastic; F, Fibroblastic; M, Meningothelial; P, Psammomatous; T, Transitional and U, Unclassified.</p><p><bold>2 </bold>Position of the mutations according to numbering of the cDNA sequence, nucleotide number one is the A in the ATG translation initiation codon [GenBank:<ext-link ext-link-type="gen" xlink:href="AF369658">AF369658</ext-link>]. Abbreviations: substitution, &#x0003e;; deletion, del; insertion, ins; No Aberration Detected, NAD. Donor splice site mutations indicated by the last nucleotide of the preceding exon, a plus sign and position in the intron (e.g. 240+2T&#x0003e;C). Acceptor splice site mutations denoted by the first nucleotide of the following exon, a minus sign and position in the intron (e.g. 241-2A&#x0003e;C).</p><p><bold>3 </bold>Amino acid number one is the translation initiator Methionine. Abbreviations: translation termination codon, X; frame shift, fs; abnormal splicing, Abn. Spl.</p><p><bold>4 </bold>Data from copy number imbalances on chromosome 1 were previously published [34]. Abbreviations: Terminal Deletion, TD; Interstitial Deletion, ID; Amplification/gain, A; Not Studied, NS; No Aberration Detected, NAD; Retained segment R. Genbank accession numbers in squared brackets.</p><p><bold>5 </bold>Loss of non-chromosome 22 clones spanning the <italic>DAL1</italic>, D1; <italic>PTCH2A</italic>, P2A; <italic>PTCH1B</italic>, P1B; <italic>SUFU1A</italic>, S1A; and <italic>SUFU1B</italic>, S1B genes.</p><p><bold>6 </bold>M64 displays a homozygous deletion of the <italic>NF2 </italic>gene.</p><p><bold>7 </bold>M11 demonstrates multiple deletions not affecting the <italic>NF2 </italic>gene.</p><p><bold>8 </bold>M34 displays a terminal deletion not affecting the <italic>NF2 </italic>locus.</p><p><bold>9 </bold>M22 presents two mutations in the <italic>NF2 </italic>locus, in exon 13 and in the CNG <italic>inter1</italic>. The position of the <italic>inter1 </italic>mutation is according to numbering on chromosome 22 (UCSC Homo sapiens Genome Browser, assembly July 2003). Ten bases on each side of the mutation: agcaaagagaCaaattaccca.</p><p><bold>10 </bold>Methylation of a single CpG site in the intron 1 of the <italic>NF2 </italic>gene in ~40% of DNA molecules.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Chromosome 22 DNA copy number status and <italic>NF2 </italic>gene mutations in a subset of 100 sporadic meningiomas.</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="2"><bold><italic>NF2 </italic>gene</bold></td><td></td></tr><tr><td></td><td colspan="2"><hr></hr></td><td></td></tr><tr><td align="left"><bold>Chr. 22 status</bold></td><td align="center"><bold>Point mutation</bold></td><td align="center"><bold>No point mutation</bold></td><td align="center"><bold>Total</bold></td></tr></thead><tbody><tr><td align="left">Monosomy</td><td align="center">32</td><td align="center">17</td><td align="center">49</td></tr><tr><td align="left">NAD<sup>1</sup></td><td align="center">3</td><td align="center">36</td><td align="center">39</td></tr><tr><td align="left">Interstitial/terminal deletion</td><td align="center">3</td><td align="center">9</td><td align="center">12</td></tr><tr><td align="left">Total</td><td align="center">38</td><td align="center">62</td><td align="center">100</td></tr></tbody></table><table-wrap-foot><p><bold>1 </bold>No Aberration Detected, NAD</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p><italic>NF2 </italic>gene mutation frequencies in meningiomas of different histological subtypes.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>Histological subtype</bold></td><td align="center"><bold>Total no.</bold></td><td align="center"><bold><italic>NF2 </italic>gene mutation frequency<sup>1</sup></bold></td><td align="center"><bold>Chr. 22 deletions affecting the <italic>NF2 </italic>gene</bold></td><td align="center"><bold>Biallelic inactivation of the <italic>NF2 </italic>gene</bold></td></tr></thead><tbody><tr><td align="left">Meningothelial</td><td align="center">33</td><td align="center">6/33 (18%)</td><td align="center">13/33 (39%)</td><td align="center">6/33 (18%)</td></tr><tr><td align="left">Transitional</td><td align="center">31</td><td align="center">13/31 (42%)</td><td align="center">20/31(65%)</td><td align="center">12/31(39%)</td></tr><tr><td align="left">Fibroblastic</td><td align="center">21</td><td align="center">11/21 (52%)</td><td align="center">18/21 (86%)<sup>4</sup></td><td align="center">11/21 (52%)<sup>5</sup></td></tr><tr><td align="left">Anaplastic</td><td align="center">8</td><td align="center">5/8 (61%)<sup>2</sup></td><td align="center">5/8 (61%)</td><td align="center">4/8(50%)</td></tr><tr><td align="left">Psammomatous</td><td align="center">4</td><td align="center">2/4 (50%)<sup>3</sup></td><td align="center">3/4 (75%)</td><td align="center">2/4 (50%)</td></tr><tr><td align="left">Unclassified</td><td align="center">3</td><td align="center">1/3 (33%)</td><td align="center">1/3 (33%)</td><td align="center">1/3 (33%)</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><bold>Overall</bold></td><td align="center">100</td><td align="center">39</td><td align="center">60</td><td align="center">36</td></tr></tbody></table><table-wrap-foot><p><bold>1 </bold>The methylation status of <italic>NF2 </italic>gene promoter in tumor M104 is not included.</p><p><bold>2 </bold>The two micro deletions (1 bp and 7 bp) detected in M169 within exon 12 are considered as one.</p><p><bold>3 </bold>Two point mutations were detected in M22, only one is used for calculations.</p><p><bold>4 </bold>Fifteen of the 18 fibroblastic meningiomas that display deletions on chromosome 22 are monosomy cases. The three remaining tumors (M64, M32, and M114) all disclose a minimum of 18 Mb deletion of 22q.</p><p><bold>5 </bold>Case M64 (biallelic deletion affecting the <italic>NF2 </italic>gene) is not included in this calculation</p></table-wrap-foot></table-wrap></sec></back></article> 